{"aaData": [["Anticoagulation Therapy for Atrial Fibrillation/Flutter", "
CMS71v4
\n", "
4
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
03876d69-085b-415c-ae9d-9924171040c2
\n", "
0436
\n", "
\nIschemic stroke patients with atrial fibrillation/flutter who are prescribed \nanticoagulation therapy at hospital discharge.\n
\n
\n", "
Individual Characteristic
\n", "
71
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Venous Thromboembolism Patients with Anticoagulation Overlap Therapy", "
CMS73v3
\n", "
3
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
6f069bb2-b3c4-4bf4-adc5-f6dd424a10b7
\n", "
0373
\n", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nwho received an overlap of parenteral (intravenous [IV] or subcutaneous \n[subcu]) anticoagulation and warfarin therapy. For patients who received \nless than five days of overlap therapy, they should be discharged on both \nmedications or have a reason for discontinuation of overlap therapy. Overlap \ntherapy should be administered for at least five days with an international \nnormalized ratio (INR) greater than or equal to 2 prior to discontinuation \nof the parenteral anticoagulation therapy, discharged on both medications \nor have a reason for discontinuation of overlap therapy.\n
\n
\n", "
Individual Characteristic
\n", "
73
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Functional Status Assessment for Knee Replacement", "
CMS66v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.  NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications.\n
\n
\n", "
\n
\n\n
\n", "
be8d9655-1194-46ef-b43e-4b1d0c36ab71
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 18 years and older with primary total knee \narthroplasty (TKA) who completed  baseline and follow-up (patient-reported) \nfunctional status assessments.\n
\n
\n", "
Individual Characteristic
\n", "
66
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Appropriate Testing for Children with Pharyngitis", "
CMS146v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
beb1c33c-2549-4e7f-9567-05ed38448464
\n", "
0002
\n", "
\nPercentage of children 2-18 years of age who were diagnosed with pharyngitis, \nordered an antibiotic and received a group A streptococcus (strep) test \nfor the episode.\n
\n
\n", "
Individual Characteristic
\n", "
146
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Low Density Lipoprotein (LDL) Management", "
CMS163v2
\n", "
2
\n", "
Diab_LDL
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
0dac1dec-e011-493b-a281-7c28964872dd
\n", "
0064
\n", "
\nPercentage of patients 1875 years of age with diabetes whose LDL-C was \nadequately controlled (<100 mg/dL) during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
163
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Diabetes: Foot Exam", "
CMS123v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
c0d72444-7c26-4863-9b51-8080f8928a85
\n", "
0056
\n", "
\nPercentage of patients aged 18-75 years of age with diabetes who had a \nfoot exam during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
123
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Initiation and Engagement of Alcohol and Other Drug Dependence Treatment", "
CMS137v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
c3657d72-21b4-4675-820a-86c7fe293bf5
\n", "
0004
\n", "
\nPercentage of patients 13 years of age and older with a new episode of \nalcohol and other drug (AOD) dependence who received the following. Two \nrates are reported.a. Percentage of patients who initiated treatment within \n14 days of the diagnosis.b. Percentage of patients who initiated treatment \nand who had two or more additional services with an AOD diagnosis within \n30 days of the initiation visit.\n
\n
\n", "
Individual Characteristic
\n", "
137
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Chlamydia Screening for Women", "
CMS153v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
c9930664-be3d-4ffe-ae4a-5cf4933ecb89
\n", "
0033
\n", "
\nPercentage of women 16-24 years of age who were identified as sexually \nactive and who had at least one test for chlamydia during the measurement \nperiod.\n
\n
\n", "
Individual Characteristic
\n", "
153
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Eye Exam", "
CMS131v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
d90bdab4-b9d2-4329-9993-5c34e2c0dc66
\n", "
0055
\n", "
\nPercentage of patients 18-75 years of age with diabetes who had a retinal \nor dilated eye exam by an eye care professional during the measurement \nperiod or a negative retinal exam (no evidence of retinopathy) in the 12 \nmonths prior to the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
131
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation", "
CMS143v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
db9d9f09-6b6a-4749-a8b2-8c1fdb018823
\n", "
0086
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of primary \nopen-angle glaucoma (POAG) who have an optic nerve head evaluation during \none or more office visits within 12 months\n
\n
\n", "
Individual Characteristic
\n", "
143
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Hypertension: Improvement in Blood Pressure", "
CMS65v3
\n", "
3
\n", "
Hypertension Improvement in BP
\n", "
National Committee for Quality Assurance (NCQA)
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.\n
\n
\n", "
\n
\n\n
\n", "
1d8363ce-a529-490b-8c98-9b54aa75da06
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 18-85 years of age with a diagnosis of hypertension \nwhose blood pressure improved during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
65
\n", "
InProgress
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["HIV/AIDS: RNA Control for Patients with HIV", "
CMS77v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.\n
\n
\n", "
\n
\n\n
\n", "
e0a07809-7b74-473f-bcc4-1891be506aaa
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, \nwith at least two visits during the measurement year, with at least 90 \ndays between each visit, whose most recent HIV RNA level is <200 copies/mL.\n
\n
\n", "
Individual Characteristic
\n", "
77
\n", "
InProgress
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Anticoagulation Therapy for Atrial Fibrillation/Flutter", "
CMS71v6
\n", "
6.2.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms(R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
03876d69-085b-415c-ae9d-9924171040c2
\n", "
0436
\n", "
\nIschemic stroke patients with atrial fibrillation/flutter who are prescribed \nanticoagulation therapy at hospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
71
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention", "
CMS138v3
\n", "
3
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
e35791df-5b25-41bb-b260-673337bc44a8
\n", "
0028
\n", "
\nPercentage of patients aged 18 years and older who were screened for tobacco \nuse one or more times within 24 months AND who received cessation counseling \nintervention if identified as a tobacco user\n
\n
\n", "
Individual Characteristic
\n", "
138
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Appropriate Treatment for Children with Upper Respiratory Infection (URI)", "
CMS154v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
e455fac0-f2cb-4074-a351-1e68a90fb7cf
\n", "
0069
\n", "
\nPercentage of children 3 months-18 years of age who were diagnosed with \nupper respiratory infection (URI) and were not dispensed an antibiotic \nprescription on or three days after the episode.\n
\n
\n", "
Individual Characteristic
\n", "
154
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Hemoglobin A1c Poor Control", "
CMS122v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
f2986519-5a4e-4149-a8f2-af0a1dc7f6bc
\n", "
0059
\n", "
\nPercentage of patients 18-75 years of age with diabetes who had hemoglobin \nA1c > 9.0% during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
122
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Pregnant women that had HBsAg testing", "
CMS158v2
\n", "
2
\n", "
Preg_HBsAg
\n", "
OptumInsight
\n", "
OptumInsight
\n", "
\nNone\n
\n
\n", "
\n
\n\n
\n", "
3bbfc929-50c8-44b8-8d34-82be75c08a70
\n", "
0608
\n", "
\nThis measure identifies pregnant women who had a HBsAg (hepatitis B) test \nduring their pregnancy.\n
\n
\n", "
Individual Characteristic
\n", "
158
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Major Depressive Disorder (MDD): Suicide Risk Assessment", "
CMS161v1
\n", "
1
\n", "
MDD_Suicide
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2012 American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
60176fbf-bfdc-4892-9c9e-604f206553c8
\n", "
0104
\n", "
\nPercentage of patients aged 18 years and older with a new diagnosis or \nrecurrent episode of MDD who had a suicide risk assessment completed at \neach visit during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
161
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Functional Status Assessment for Total Hip Replacement", "
CMS56v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets. NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications. \nCPT(R) contained in the Measure specifications is copyright 2004-2015 American \nMedical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2015 International Health Terminology Standards Development Organisation. \nICD-10 copyright 2015 World Health Organization. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
2f291003-3f2f-48af-bef9-e5aacb95ac3e
\n", "
Not Applicable
\n", "
\nPercentage of patients 18 years of age and older with primary total hip \narthroplasty (THA) who completed baseline and follow-up patient-reported \nfunctional status assessments\n
\n
\n", "
Individual Characteristic
\n", "
56
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Incidence of Potentially-Preventable Venous Thromboembolism", "
CMS114v5
\n", "
5.1.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
32cfc834-843a-4f45-b359-8e158eac4396
\n", "
Not Applicable
\n", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nduring hospitalization (not present at admission) who did not receive VTE \nprophylaxis between hospital admission and the day before the VTE diagnostic \ntesting order date\n
\n
\n", "
Medication
\n", "
114
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
FY 2014 EH
\n"], ["Dementia: Cognitive Assessment", "
CMS149v1
\n", "
1
\n", "
Dementia_Cognitive
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2012 American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
7c443b9b-1ad1-4467-b527-defc445701ff
\n", "
Not Applicable
\n", "
\nPercentage of patients, regardless of age, with a diagnosis of dementia \nfor whom an assessment of cognition is performed and the results reviewed \nat least once within a 12 month period.\n
\n
\n", "
Risk Category/Assessment
\n", "
149
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Assessed for Rehabilitation", "
CMS102v3
\n", "
3
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
7dc26160-e615-4cc2-879c-75985189ec1a
\n", "
0441
\n", "
\nIschemic or hemorrhagic stroke patients who were assessed for rehabilitation \nservices.\n
\n
\n", "
Individual Characteristic
\n", "
102
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control", "
CMS182v3
\n", "
2
\n", "
IVD_Lipid_LDL
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
500e4792-7f94-4e34-8546-ee71c56fe463
\n", "
0075
\n", "
\nPercentage of patients 18 years of age and older who were discharged alive \nfor acute myocardial infarction (AMI), coronary artery bypass graft (CABG) \nor percutaneous coronary interventions (PCI) in the 12 months prior to \nthe measurement period, or who had an active diagnosis of ischemic vascular \ndisease (IVD) during the measurement period, and who had a complete lipid \nprofile performed during the measurement period and whose LDL-C was adequately \ncontrolled (< 100 mg/dL).\n
\n
\n", "
Individual Characteristic
\n", "
182
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Depression Remission at Twelve Months", "
CMS159v1
\n", "
1
\n", "
Dep_Rem_12
\n", "
Minnesota Community Measurement
\n", "
Minnesota Community Measurement
\n", "
\nCopyright MN Community Measurement, 2012. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
8455cd3e-dbb9-4e0c-8084-3ece4068fe94
\n", "
0710
\n", "
\nAdult patients age 18 and older with major depression or dysthymia and \nan initial PHQ-9 score > 9 who demonstrate remission at twelve months defined \nas PHQ-9 score less than 5. This measure applies to both patients with \nnewly diagnosed and existing depression whose current PHQ-9 score indicates \na need for treatment.\n
\n
\n", "
Attribute
\n", "
159
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment", "
CMS177v1
\n", "
1
\n", "
CA MDD SRA
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2012 American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
848d09de-7e6b-43c4-bedd-5a2957ccffe3
\n", "
1365
\n", "
\nPercentage of patient visits for those patients aged 6 through 17 years \nwith adiagnosis of major depressive disorder with an assessment for suicide \nrisk\n
\n
\n", "
Individual Characteristic
\n", "
177
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Anti-depressant Medication Management", "
CMS128v1
\n", "
1
\n", "
Antidep_Med_Mgmt
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
8924f2b3-ec06-4650-b634-d70a53dee577
\n", "
0105
\n", "
\nPercentage of patients 18 years of age and older who were diagnosed with \nmajor depression and treated with antidepressant medication, and who remained \non antidepressant medication treatment. Two rates are reported. a. Percentage \nof patients who remained on an antidepressant medication for at least 84 \ndays (12 weeks). b. Percentage of patients who remained on an antidepressant \nmedication for at least 180 days (6 months).\n
\n
\n", "
Individual Characteristic
\n", "
128
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care", "
CMS142v2
\n", "
2
\n", "
Diab_Retin_Comm
\n", "
National Committee for Quality Assurance
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2012 American Medical Association and National Committee for \nQuality Assurance. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
53d6d7c3-43fb-4d24-8099-17e74c022c05
\n", "
0089
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of diabetic \nretinopathy who had a dilated macular or fundus exam performed with documented \ncommunication to the physician who manages the ongoing care of the patient \nwith diabetes mellitus regarding the findings of the macular or fundus \nexam at least once within 12 months\n
\n
\n", "
Individual Characteristic
\n", "
142
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Hearing Screening Prior To Hospital Discharge", "
CMS31v4
\n", "
4.0.000
\n", "", "
CDC Early Hearing Detection and Intervention Program
\n", "
CDC National Center on Birth Defects and Developmental Disabilities
\n", "
\nNone\n
\n
\n", "
\n
\n\n
\n", "
0924fbae-3fdb-4d0a-aab7-9f354e699fde
\n", "
1354
\n", "
\nThis measure assesses the proportion of births that have been screened \nfor hearing loss before hospital discharge.\n
\n
\n", "
Individual Characteristic
\n", "
31
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up", "
CMS69v1
\n", "
1
\n", "
0421
\n", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
9a031bb8-3d9b-11e1-8634-00237d5bf174
\n", "
0421
\n", "
\nPercentage of patients aged 18 years and older with an encounter during \nthe reporting period with a documented calculated BMI during the encounter \nor during the previous six months, AND when the BMI is outside of normal \nparameters, follow-up is documented during the encounter or during the \nprevious six months of the encounter with the BMI outside of normal parameters.Normal \nParameters:       Age 65 years and older BMI => 23 and < 30            \n                         Age 18  64 years BMI => 18.5 and < 25\n
\n
\n", "
Individual Characteristic
\n", "
69
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan", "
CMS2v1
\n", "
1
\n", "
NQF418
\n", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
9a031e24-3d9b-11e1-8634-00237d5bf174
\n", "
0418
\n", "
\nPercentage of patients aged 12 years and older screened for clinical depression \non the date of the encounter using an age appropriate standardized depression \nscreening tool AND if positive, a follow-up plan is documented on the date \nof the positive screen.\n
\n
\n", "
Individual Characteristic
\n", "
2
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Venous Thromboembolism Discharge Instructions", "
CMS110v3
\n", "
3
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
7fe69617-fa28-4305-a2b8-ceb6bcd9693d
\n", "", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nthat are discharged to home, home care, court/law enforcement or home on \nhospice care on warfarin with written discharge instructions that address \nall four criteria: compliance issues, dietary advice, follow-up monitoring, \nand information about the potential for adverse drug reactions/interactions.\n
\n
\n", "
Individual Characteristic
\n", "
110
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented", "
CMS22v1
\n", "
1
\n", "
BP Screening
\n", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
9a033a94-3d9b-11e1-8634-00237d5bf174
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 18 years and older seen during the reporting \nperiod who were screened for high blood pressure AND a recommended follow-up \nplan is documented based on the current blood pressure (BP) reading as \nindicated\n
\n
\n", "
Individual Characteristic
\n", "
22
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Depression Utilization of the PHQ-9 Tool", "
CMS160v1
\n", "
1
\n", "
Dep_PHQ-9
\n", "
Minnesota Community Measurement
\n", "
Minnesota Community Measurement
\n", "
\nCopyright MN Community Measurement, 2012. All rights reserved\n
\n
\n", "
\n
\n\n
\n", "
a4b9763c-847e-4e02-bb7e-acc596e90e2c
\n", "
0712
\n", "
\nAdult patients age 18 and older with the diagnosis of major depression \nor dysthymia who have a PHQ-9 tool administered at least once during a \n4 month period in which there was a qualifying visit.\n
\n
\n", "
Attribute
\n", "
160
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication", "
CMS136v3
\n", "
3
\n", "
ADHD_Follow-Up
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
703cc49b-b653-4885-80e8-245a057f5ae9
\n", "
0108
\n", "
\nPercentage of children 6-12 years of age and newly dispensed a medication \nfor attention-deficit/hyperactivity disorder (ADHD) who had appropriate \nfollow-up care.  Two rates are reported.  a. Percentage of children who \nhad one follow-up visit with a practitioner with prescribing authority \nduring the 30-Day Initiation Phase.b. Percentage of children who remained \non ADHD medication for at least 210 days and who, in addition to the visit \nin the Initiation Phase, had at least two additional follow-up visits with \na practitioner within 270 days (9 months) after the Initiation Phase ended.\n
\n
\n", "
Attribute
\n", "
136
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Urine Protein Screening", "
CMS134v2
\n", "
2
\n", "
Diab_Urine
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
7b2a9277-43da-4d99-9bee-6ac271a07747
\n", "
0062
\n", "
\nThe percentage of patients 18-75 years of age with diabetes who had a nephropathy \nscreening test or evidence of nephropathy during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
134
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis", "
CMS52v4
\n", "
4.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nCopyright 2014 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
1cdd20de-5de9-4759-8a93-31f1f8baaaa2
\n", "
0405
\n", "
\nPercentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS \nwho were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis\n
\n
\n", "
Individual Characteristic
\n", "
52
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients", "
CMS188v4
\n", "
4
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
8243eae0-bbd7-4107-920b-fc3db04b9584
\n", "
0147
\n", "
\n(PN-6) Immunocompetent patients with Community-Acquired Pneumonia who receive \nan initial antibiotic regimen during the first 24 hours that is consistent \nwith current guidelines (Population 1) Immunocompetent ICU patients with \nCommunity-Acquired Pneumonia who receive an initial antibiotic regimen \nduring the first 24 hours that is consistent with current guidelines(Population \n2) Immunocompetent non-Intensive Care Unit (ICU) patients with Community-Acquired \nPneumonia who receive an initial antibiotic regimen during the first 24 \nhours that is consistent with current guidelines\n
\n
\n", "
Individual Characteristic
\n", "
188
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Discharged on Statin Medication", "
CMS105v4
\n", "
4.0.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT[C]) copyright 2004-2014 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
1f503318-bb8d-4b91-af63-223ae0a2328e
\n", "
0439
\n", "
\nIschemic stroke patients who are prescribed statin medication at hospital \ndischarge.\n
\n
\n", "
Medication
\n", "
105
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Depression Remission at Twelve Months", "
CMS159v2
\n", "
2
\n", "
Dep_Rem_12
\n", "
Minnesota Community Measurement
\n", "
Minnesota Community Measurement
\n", "
\nCopyright MN Community Measurement, 2012. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
8455cd3e-dbb9-4e0c-8084-3ece4068fe94
\n", "
0710
\n", "
\nAdult patients age 18 and older with major depression or dysthymia and \nan initial PHQ-9 score > 9 who demonstrate remission at twelve months defined \nas PHQ-9 score less than 5. This measure applies to both patients with \nnewly diagnosed and existing depression whose current PHQ-9 score indicates \na need for treatment\n
\n
\n", "
Attribute
\n", "
159
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Thrombolytic Therapy", "
CMS91v5
\n", "
5.0.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2014 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
2838875a-07b5-4bf0-be04-c3eb99f53975
\n", "
0437
\n", "
\nAcute ischemic stroke patients who arrive at this hospital within 2 hours \nof time last known well and for whom t-PA was initiated at this hospital \nwithin 3 hours of time last known well.\n
\n
\n", "
Medication
\n", "
91
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Venous Thromboembolism Prophylaxis", "
CMS108v4
\n", "
4.0.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT[C]) copyright 2004-2014 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
38b0b5ec-0f63-466f-8fe3-2cd20ddd1622
\n", "
0371
\n", "
\nThis measure assesses the number of patients who received VTE prophylaxis \nor have documentation why no VTE prophylaxis was given the day of or the \nday after hospital admission or surgery end date for surgeries that start \nthe day of or the day after hospital admission.\n
\n
\n", "
Medication
\n", "
108
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Initiation and Engagement of Alcohol and Other Drug Dependence Treatment", "
CMS137v1
\n", "
1
\n", "
Ini_Eng_Alc_Drug_Dep
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
c3657d72-21b4-4675-820a-86c7fe293bf5
\n", "
0004
\n", "
\nPercentage of patients 13 years of age and older with a new episode of \nalcohol and other drug (AOD) dependence who received the following. Two \nrates are reported.a. Percentage of patients who initiated treatment within \n14 days of the diagnosis.b. Percentage of patients who initiated treatment \nand who had two or more additional services with an AOD diagnosis within \n30 days of the initiation visit.\n
\n
\n", "
Individual Characteristic
\n", "
137
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Hemoglobin A1c Test for Pediatric Patients", "
CMS148v2
\n", "
2
\n", "
HA1c_Ped
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
95fb767e-0cb2-4778-b5ff-6ba9a53fa28e
\n", "
0060
\n", "
\nPercentage of patients 5-17 years of age with diabetes with an HbA1c test \nduring the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
148
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Primary PCI Received Within 90 Minutes of Hospital Arrival", "
CMS53v3
\n", "
3
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
84b9d0b5-0caf-4e41-b345-3492a23c2e9f
\n", "
0163
\n", "
\nAcute myocardial infarction (AMI) patients with ST-segment elevation on \nthe ECG closest to arrival time receiving primary PCI during the hospital \nstay with a time from hospital arrival to PCI of 90 minutes or less.\n
\n
\n", "
Individual Characteristic
\n", "
53
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention", "
CMS138v1
\n", "
1
\n", "
Tobacco
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2012 American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
e35791df-5b25-41bb-b260-673337bc44a8
\n", "
0028
\n", "
\nPercentage of patients aged 18 years and older who were screened for tobacco \nuse one or more times within 24 months AND who received cessation counseling \nintervention if identified as a tobacco user\n
\n
\n", "
Individual Characteristic
\n", "
138
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures", "
CMS132v2
\n", "
2
\n", "
Cataracts
\n", "
National Committee for Quality Assurance
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2012 American Medical Association and National Committee for \nQuality Assurance. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
9a0339c2-3d9b-11e1-8634-00237d5bf174
\n", "
0564
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of uncomplicated \ncataract who had cataract surgery and had any of a specified list of surgical \nprocedures in the 30 days following cataract surgery which would indicate \nthe occurrence of any of the following major complications: retained nuclear \nfragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, \nor wound dehiscence\n
\n
\n", "
Individual Characteristic
\n", "
132
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival", "
CMS60v3
\n", "
3
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
909cf4b4-7a85-4abf-a1c7-cb597ed1c0b6
\n", "
0164
\n", "
\nAcute myocardial infarction (AMI) patients with ST-segment elevation on \nthe ECG closest to arrival time receiving fibrinolytic therapy during the \nhospital stay and having a time from hospital arrival to fibrinolysis of \n30 minutes or less.\n
\n
\n", "
Individual Characteristic
\n", "
60
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Depression Utilization of the PHQ-9 Tool", "
CMS160v2
\n", "
2
\n", "
Dep_PHQ-9
\n", "
Minnesota Community Measurement
\n", "
Minnesota Community Measurement
\n", "
\nCopyright MN Community Measurement, 2012. All rights reserved\n
\n
\n", "
\n
\n\n
\n", "
a4b9763c-847e-4e02-bb7e-acc596e90e2c
\n", "
0712
\n", "
\nAdult patients age 18 and older with the diagnosis of major depression \nor dysthymia who have a PHQ-9 tool administered at least once during a \n4-month period in which there was a qualifying visit.\n
\n
\n", "
Attribute
\n", "
160
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Childhood Immunization Status", "
CMS117v2
\n", "
2
\n", "
Child_Imm_Status
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
b2802b7a-3580-4be8-9458-921aea62b78c
\n", "
0038
\n", "
\nPercentage of children 2 years of age who had four diphtheria, tetanus \nand acellular pertussis (DTaP); three polio (IPV), one measles, mumps and \nrubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); \none chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis \nA (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines \nby their second birthday.\n
\n
\n", "
Individual Characteristic
\n", "
117
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Antithrombotic Therapy By End of Hospital Day 2", "
CMS72v3
\n", "
3
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
93f3479f-75d8-4731-9a3f-b7749d8bcd37
\n", "
0438
\n", "
\nIschemic stroke patients administered antithrombotic therapy by the end \nof hospital day 2.\n
\n
\n", "
Individual Characteristic
\n", "
72
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Exclusive Breast Milk Feeding", "
CMS9v4
\n", "
4.0.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nLOINC(R) is a registered trademark of the Regenstrief Institute. This material \ncontains SNOMED Clinical Terms (R) (SNOMED CT[C]) copyright 2004-2014 International \nHealth Terminology Standards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
7d374c6a-3821-4333-a1bc-4531005d77b8
\n", "
0480
\n", "
\nPC-05 Exclusive breast milk feeding during the newborn's entire hospitalization.PC-05a \nExclusive breast milk feeding during the newborn's entire hospitalization \nconsidering mother's choice.\n
\n
\n", "
Condition/Diagnosis/Problem
\n", "
9
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Diabetes: Foot Exam", "
CMS123v2
\n", "
2
\n", "
Diab_Foot
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
c0d72444-7c26-4863-9b51-8080f8928a85
\n", "
0056
\n", "
\nPercentage of patients aged 18-75 years of age with diabetes who had a \nfoot exam during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
123
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Eye Exam", "
CMS131v2
\n", "
2
\n", "
Diab_Eye
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
d90bdab4-b9d2-4329-9993-5c34e2c0dc66
\n", "
0055
\n", "
\nPercentage of patients 18-75 years of age with diabetes who had a retinal \nor dilated eye exam by an eye care professional during the measurement \nperiod or a negative retinal exam (no evidence of retinopathy) in the 12 \nmonths prior to the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
131
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients", "
CMS188v5
\n", "
5.1.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain  CPT(R) is a trademark \nof the American Medical Association. Current Procedural Terminology. (CPT) \nis copyright 2014 American Medical Association. All rights reserved. No \nfee schedules, basic units, relative values, or related listings are included \nin CPT. The AMA assumes no liability for the data contained herein. Applicable \nFARS/DFARS restrictions apply to government use.  LOINC(R) is a registered \ntrademark of the Regenstrief Institute.  This material contains SNOMED \nClinical Terms (R) (SNOMED CT(C)) copyright 2004-2014 International Health \nTerminology Standards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
8243eae0-bbd7-4107-920b-fc3db04b9584
\n", "
0147
\n", "
\n(PN-6) Immunocompetent patients with Community-Acquired Pneumonia who receive \nan initial antibiotic regimen during the first 24 hours that is consistent \nwith current guidelines (Population 1) Immunocompetent ICU patients with \nCommunity-Acquired Pneumonia who receive an initial antibiotic regimen \nduring the first 24 hours that is consistent with current guidelines(Population \n2) Immunocompetent non-Intensive Care Unit (ICU) patients with Community-Acquired \nPneumonia who receive an initial antibiotic regimen during the first 24 \nhours that is consistent with current guidelines\n
\n
\n", "
Procedure
\n", "
188
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Depression Remission at Twelve Months", "
CMS159v4
\n", "
4.0.000
\n", "", "
MN Community Measurement
\n", "
MN Community Measurement
\n", "
\nCopyright MN Community Measurement, 2015. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
8455cd3e-dbb9-4e0c-8084-3ece4068fe94
\n", "
0710
\n", "
\nAdult patients age 18 and older with major depression or dysthymia and \nan initial PHQ-9 score > 9 who demonstrate remission at twelve months defined \nas PHQ-9 score less than 5. This measure applies to both patients with \nnewly diagnosed and existing depression whose current PHQ-9 score indicates \na need for treatment\n
\n
\n", "
Individual Characteristic
\n", "
159
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet", "
CMS164v5
\n", "
5.2.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
0713ea8f-0e5b-4099-8c7c-dd677280398f
\n", "
0068
\n", "
\nPercentage of patients 18 years of age and older who were diagnosed with \nacute myocardial infarction (AMI), coronary artery bypass graft (CABG) \nor percutaneous coronary interventions (PCI) in the 12 months prior to \nthe measurement period, or who had an active diagnosis of ischemic vascular \ndisease (IVD) during the measurement period, and who had documentation \nof use of aspirin or another antiplatelet during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
164
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Hemoglobin A1c Poor Control", "
CMS122v2
\n", "
2
\n", "
Diab_HbA1c_Ctrl
\n", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
f2986519-5a4e-4149-a8f2-af0a1dc7f6bc
\n", "
0059
\n", "
\nPercentage of patients 18-75 years of age with diabetes who had hemoglobin \nA1c > 9.0% during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
122
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Primary PCI Received Within 90 Minutes of Hospital Arrival", "
CMS53v4
\n", "
4.0.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain.This material contains \nSNOMED Clinical Terms (R) (SNOMED CT(C)) copyright 2004-2014 International \nHealth Terminology Standards Development Organization. All rights reserved.LOINC \n(R) is a registered trademark of the Regenstrief Institute.\n
\n
\n", "
\n
\n\n
\n", "
84b9d0b5-0caf-4e41-b345-3492a23c2e9f
\n", "
0163
\n", "
\nAcute myocardial infarction (AMI) patients with ST-segment elevation on \nthe ECG closest to arrival time receiving primary PCI during the hospital \nstay with a time from hospital arrival to PCI of 90 minutes or less.\n
\n
\n", "
Procedure
\n", "
53
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Hemoglobin A1c Test for Pediatric Patients", "
CMS148v4
\n", "
4.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2015 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2014 American Medical Association. LOINC(R) copyright 2004-2014 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2014 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2014 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
95fb767e-0cb2-4778-b5ff-6ba9a53fa28e
\n", "
0060
\n", "
\nPercentage of patients 5-17 years of age with diabetes with an HbA1c test \nduring the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
148
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Hearing Screening Prior To Hospital Discharge", "
CMS31v5
\n", "
5.1.000
\n", "", "
CDC Early Hearing Detection and Intervention Program
\n", "
CDC National Center on Birth Defects and Developmental Disabilities
\n", "
\nNone\n
\n
\n", "
\n
\n\n
\n", "
0924fbae-3fdb-4d0a-aab7-9f354e699fde
\n", "
1354
\n", "
\nThis measure assesses the proportion of births that have been screened \nfor hearing loss before hospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
31
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Depression Utilization of the PHQ-9 Tool", "
CMS160v4
\n", "
4.1.000
\n", "", "
MN Community Measurement
\n", "
MN Community Measurement
\n", "
\nCopyright MN Community Measurement, 2015. All rights reserved\n
\n
\n", "
\n
\n\n
\n", "
a4b9763c-847e-4e02-bb7e-acc596e90e2c
\n", "
0712
\n", "
\nAdult patients age 18 and older with the diagnosis of major depression \nor dysthymia who have a PHQ-9 tool administered at least once during a \n4-month period in which there was a qualifying visit.\n
\n
\n", "
Individual Characteristic
\n", "
160
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Risk-Stratified Cholesterol -Fasting Low Density Lipoprotein (LDL-C)", "
CMS64v6
\n", "
6.0.000
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nOrganization. All Rights Reserved.Due to technical limitations, registered \ntrademarks are indicated by (R) or [R] and unregistered trademarks are \nindicated by (TM) or [TM].\nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R]) or other coding contained in the specifications.CPT (R) contained \nin the Measure specifications is copyright 2007- 2016 American Medical \nAssociation. LOINC (R) copyright 2004-2015 [2.54] Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms (R) (SNOMED CT [R]) copyright \n2004-2015 [2015-09] International Health Terminology Standards Development \n
\n
\n", "
\n
\n\n
\n", "
0336a17b-7c2a-48fc-a657-e9b04269a4cc
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 20 through 79 years who had a fasting LDL-C \ntest performed and whose risk-stratified fasting LDL-C is at or below the \nrecommended LDL-C goal.\n
\n
\n", "
Individual Characteristic
\n", "
64
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Aspirin Prescribed at Discharge", "
CMS100v3
\n", "
3
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
bb481284-30dd-4383-928c-82385bbf1b17
\n", "
0142
\n", "
\nAcute myocardial infarction (AMI) patients who are prescribed aspirin at \nhospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
100
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Anticoagulation Therapy for Atrial Fibrillation/Flutter", "
CMS71v3
\n", "
3
\n", "
STK-3 (Stroke)
\n", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
03876d69-085b-415c-ae9d-9924171040c2
\n", "
0436
\n", "
\nIschemic stroke patients with atrial fibrillation/flutter who are prescribed \nanticoagulation therapy at hospital discharge.\n
\n
\n", "
Individual Characteristic
\n", "
71
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Hearing Screening Prior To Hospital Discharge (EHDI-1a)", "
CMS31v2
\n", "
2
\n", "
Supplemental Value Sets
\n", "
CDC Early Hearing Detection and Intervention Program
\n", "
CDC National Center on Birth Defects and Developmental Disabilities
\n", "
\nNone\n
\n
\n", "
\n
\n\n
\n", "
0924fbae-3fdb-4d0a-aab7-9f354e699fde
\n", "
1354
\n", "
\nThis measure assesses the proportion of births that have been screened \nfor hearing loss before hospital discharge.\n
\n
\n", "
Individual Characteristic
\n", "
31
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Discharged on Statin Medication", "
CMS105v2
\n", "
2
\n", "
Discharged on Statin Medication
\n", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
1f503318-bb8d-4b91-af63-223ae0a2328e
\n", "
0439
\n", "
\nIschemic stroke patients with LDL greater than or equal to 100 mg/dL, or \nLDL not measured, or who were on a lipid-lowering medication prior to hospital \narrival are prescribed statin medication at hospital discharge.\n
\n
\n", "
Individual Characteristic
\n", "
105
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Stroke Education", "
CMS107v2
\n", "
2
\n", "
Stroke Education
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
217fdf0d-3d64-4720-9116-d5e5afa27f2c
\n", "
0440
\n", "
\nIschemic or hemorrhagic stroke patients or their caregivers who were given \neducational materials during the hospital stay addressing all of the following: \nactivation of emergency medical system, need for follow-up after discharge, \nmedications prescribed at discharge, risk factors for stroke, and warning \nsigns and symptoms of stroke.\n
\n
\n", "
Individual Characteristic
\n", "
107
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Thrombolytic Therapy", "
CMS91v3
\n", "
3
\n", "
STK-4
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
2838875a-07b5-4bf0-be04-c3eb99f53975
\n", "
0437
\n", "
\nAcute ischemic stroke patients who arrive at this hospital within 2 hours \nof time last known well and for whom IV t-PA was initiated at this hospital \nwithin 3 hours of time last known well.\n
\n
\n", "
Individual Characteristic
\n", "
91
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Incidence of Potentially-Preventable Venous Thromboembolism", "
CMS114v2
\n", "
2
\n", "
VTE-6
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
32cfc834-843a-4f45-b359-8e158eac4396
\n", "
0376
\n", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nduring hospitalization (not present at admission) who did not receive VTE \nprophylaxis between hospital admission and the day before the VTE diagnostic \ntesting order date.\n
\n
\n", "
Individual Characteristic
\n", "
114
\n", "
Complete
\n", "
OUTCOME
\n", "
FY 2014 EH
\n"], ["Venous Thromboembolism Prophylaxis", "
CMS108v2
\n", "
2
\n", "
Venous Thromboembolism Prophyla
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
38b0b5ec-0f63-466f-8fe3-2cd20ddd1622
\n", "
0371
\n", "
\nThis measure assesses the number of patients who received VTE prophylaxis \nor have documentation why no VTE prophylaxis was given the day of or the \nday after hospital admission or surgery end date for surgeries that start \nthe day of or the day after hospital admission.\n
\n
\n", "
Individual Characteristic
\n", "
108
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Median Time from ED Arrival to ED Departure for Discharged ED Patients", "
CMS32v3
\n", "
3
\n", "
Supplemental Value Sets
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nNone\n
\n
\n", "
\n
\n\n
\n", "
3fd13096-2c8f-40b5-9297-b714e8de9133
\n", "
0496
\n", "
\nMedian time from emergency department arrival to time of departure from \nthe emergency room for patients discharged from the emergency department.\n
\n
\n", "
Individual Characteristic
\n", "
32
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram", "
CMS109v3
\n", "
3
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
bcce43dd-08e3-46c3-bfdd-0b1b472690f0
\n", "", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nwho received intravenous (IV) UFH therapy dosages AND had their platelet \ncounts monitored using defined parameters such as a nomogram or protocol.\n
\n
\n", "
Individual Characteristic
\n", "
109
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Discharged on Antithrombotic Therapy", "
CMS104v2
\n", "
2
\n", "
Discharged on Antithrombotic The
\n", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
42bf391f-38a3-4c0f-9ece-dcd47e9609d9
\n", "
0435
\n", "
\nIschemic stroke patients prescribed antithrombotic therapy at hospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
104
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Venous Thromboembolism Patients with Anticoagulation Overlap Therapy", "
CMS73v2
\n", "
2
\n", "
VTE 3
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
6f069bb2-b3c4-4bf4-adc5-f6dd424a10b7
\n", "
0373
\n", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nwho received an overlap of parenteral (intravenous [IV] or subcutaneous \n[subcu]) anticoagulation and warfarin therapy. For patients who received \nless than five days of overlap therapy, they should be discharged on both \nmedications or have a reason for discontinuation of overlap therapy. Overlap \ntherapy should be administered for at least five days with an international \nnormalized ratio (INR) greater than or equal to 2 prior to discontinuation \nof the parenteral anticoagulation therapy, discharged on both medications \nor have a reason for discontinuation of overlap therapy.\n
\n
\n", "
Individual Characteristic
\n", "
73
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Exclusive Breast Milk Feeding", "
CMS9v2
\n", "
2
\n", "
Exclusive Breast Milk Feeding
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nLOINC(R) is a registered trademark of the Regenstrief Institute.\n
\n
\n", "
\n
\n\n
\n", "
7d374c6a-3821-4333-a1bc-4531005d77b8
\n", "
0480
\n", "
\nPC-05 Exclusive breast milk feeding during the newborn's entire hospitalizationPC-05a \nExclusive breast milk feeding during the newborns entire hospitalization \nconsidering mothers choice\n
\n
\n", "
Condition/Diagnosis/Problem
\n", "
9
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Assessed for Rehabilitation", "
CMS102v2
\n", "
2
\n", "
Assessed for Rehabilitation
\n", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
7dc26160-e615-4cc2-879c-75985189ec1a
\n", "
0441
\n", "
\nIschemic or hemorrhagic stroke patients who were assessed for rehabilitation \nservices.\n
\n
\n", "
Individual Characteristic
\n", "
102
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Venous Thromboembolism Discharge Instructions", "
CMS110v2
\n", "
2
\n", "
Venous Thromboembolism Discharge
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
7fe69617-fa28-4305-a2b8-ceb6bcd9693d
\n", "
0375
\n", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nthat are discharged to home, home care, court/law enforcement or home on \nhospice care on warfarin with written discharge instructions that address \nall four criteria: compliance issues, dietary advice, follow-up monitoring, \nand information about the potential for adverse drug reactions/interactions.\n
\n
\n", "
Individual Characteristic
\n", "
110
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients", "
CMS188v3
\n", "
3
\n", "
PN 6
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
8243eae0-bbd7-4107-920b-fc3db04b9584
\n", "
0147
\n", "
\n(PN-6) Immunocompetent patients with Community-Acquired Pneumonia who receive \nan initial antibiotic regimen during the first 24 hours that is consistent \nwith current guidelines (Population 1) Immunocompetent ICU patients with \nCommunity-Acquired Pneumonia who receive an initial antibiotic regimen \nduring the first 24 hours that is consistent with current guidelines(Population \n2) Immunocompetent non-Intensive Care Unit (ICU) patients with Community-Acquired \nPneumonia who receive an initial antibiotic regimen during the first 24 \nhours that is consistent with current guidelines\n
\n
\n", "
Individual Characteristic
\n", "
188
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Primary PCI Received Within 90 Minutes of Hospital Arrival", "
CMS53v2
\n", "
2
\n", "
AMI-8a
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
84b9d0b5-0caf-4e41-b345-3492a23c2e9f
\n", "
0163
\n", "
\nAcute myocardial infarction (AMI) patients with ST-segment elevation or \nLBBB on the ECG closest to arrival time receiving primary PCI during the \nhospital stay with a time from hospital arrival to PCI of 90 minutes or \nless.\n
\n
\n", "
Individual Characteristic
\n", "
53
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival", "
CMS60v2
\n", "
2
\n", "
Fibrinolytic Therapy
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
909cf4b4-7a85-4abf-a1c7-cb597ed1c0b6
\n", "
0164
\n", "
\nAcute myocardial infarction (AMI) patients with ST-segment elevation or \nLBBB on the ECG closest to arrival time receiving fibrinolytic therapy \nduring the hospital stay and having a time from hospital arrival to fibrinolysis \nof 30 minutes or less\n
\n
\n", "
Individual Characteristic
\n", "
60
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Antithrombotic Therapy By End of Hospital Day 2", "
CMS72v2
\n", "
2
\n", "
SKT-5 (Stroke)
\n", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
93f3479f-75d8-4731-9a3f-b7749d8bcd37
\n", "
0438
\n", "
\nIschemic stroke patients administered antithrombotic therapy by the end \nof hospital day 2.\n
\n
\n", "
Individual Characteristic
\n", "
72
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Median Admit Decision Time to ED Departure Time for Admitted Patients", "
CMS111v2
\n", "
2
\n", "
Supplemental Value Sets
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
979f21bd-3f93-4cdd-8273-b23dfe9c0513
\n", "
0497
\n", "
\nMedian time (in minutes) from admit decision time to time of departure \nfrom the emergency department for emergency department patients admitted \nto inpatient status.\n
\n
\n", "
Individual Characteristic
\n", "
111
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision", "
CMS171v4
\n", "
4
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
d09add1d-30f5-462d-b677-3d17d9ccd664
\n", "
0527
\n", "
\nSurgical patients with prophylactic antibiotics initiated within one hour \nprior to surgical incision. Patients who received vancomycin or a fluoroquinolone \nfor prophylactic antibiotics should have the antibiotics initiated within \ntwo hours prior to surgical incision. Due to the longer infusion time required \nfor vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics \nwithin two hours prior to incision time.\n
\n
\n", "
Individual Characteristic
\n", "
171
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Median Time from ED Arrival to ED Departure for Admitted ED Patients", "
CMS55v2
\n", "
2
\n", "
Supplemental Value Sets
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
9a033274-3d9b-11e1-8634-00237d5bf174
\n", "
0495
\n", "
\nMedian time from emergency department arrival to time of departure from \nthe emergency room for patients admitted to the facility from the emergency \ndepartment.\n
\n
\n", "
Individual Characteristic
\n", "
55
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Aspirin Prescribed at Discharge", "
CMS100v2
\n", "
2
\n", "
AMI-2
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
bb481284-30dd-4383-928c-82385bbf1b17
\n", "
0142
\n", "
\nAcute myocardial infarction (AMI) patients who are prescribed aspirin at \nhospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
100
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram", "
CMS109v2
\n", "
2
\n", "
Venous Thromboembolism Patients
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
bcce43dd-08e3-46c3-bfdd-0b1b472690f0
\n", "
0374
\n", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nwho received intravenous (IV) UFH therapy dosages AND had their platelet \ncounts monitored using defined parameters such as a nomogram or protocol.\n
\n
\n", "
Individual Characteristic
\n", "
109
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision", "
CMS171v3
\n", "
3
\n", "
SCIP Prophylactic Antibiotic 1 H
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
d09add1d-30f5-462d-b677-3d17d9ccd664
\n", "
0527
\n", "
\nSurgical patients with prophylactic antibiotics initiated within one hour \nprior to surgical incision. Patients who received vancomycin or a fluoroquinolone \nfor prophylactic antibiotics should have the antibiotics initiated within \ntwo hours prior to surgical incision. Due to the longer infusion time required \nfor vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics \nwithin two hours prior to incision time.\n
\n
\n", "
Individual Characteristic
\n", "
171
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero", "
CMS178v3
\n", "
3
\n", "
Urinary catheter removed postop
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
d78ce034-8288-4012-a31e-7f485a74f2a9
\n", "
0453
\n", "
\nSurgical patients with urinary catheter removed on Postoperative Day 1 \nor Postoperative Day 2 with day of surgery being day zero.\n
\n
\n", "
Individual Characteristic
\n", "
178
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Statin Prescribed at Discharge", "
CMS30v3
\n", "
3
\n", "
AMI-10
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
ebfa203e-acc1-4228-906c-855c4bf11310
\n", "
0639
\n", "
\nAcute myocardial infarction (AMI) patients who are prescribed a statin \nat hospital discharge.\n
\n
\n", "
Individual Characteristic
\n", "
30
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Intensive Care Unit Venous Thromboembolism Prophylaxis", "
CMS190v2
\n", "
2
\n", "
VTE-2
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
fa91ba68-1e66-4a23-8eb2-baa8e6df2f2f
\n", "
0372
\n", "
\nThis measure assesses the number of patients who received VTE prophylaxis \nor have documentation why no VTE prophylaxis was given the day of or the \nday after the initial admission (or transfer) to the Intensive Care Unit \n(ICU) or surgery end date for surgeries that start the day of or the day \nafter ICU admission (or transfer).\n
\n
\n", "
Individual Characteristic
\n", "
190
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Elective Delivery", "
CMS113v2
\n", "
2
\n", "
Elective Delivery
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
fd7ca18d-b56d-4bca-af35-71ce36b15246
\n", "
0469
\n", "
\nPatients with elective vaginal deliveries or elective cesarean sections \nat >= 37 and < 39 weeks of gestation completed\n
\n
\n", "
Individual Characteristic
\n", "
113
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Prophylactic Antibiotic Selection for Surgical Patients", "
CMS172v3
\n", "
3
\n", "
SCIP Antibiotic Selection
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
feea3922-f61f-4b05-98f9-b72a11815f12
\n", "
0528
\n", "
\nSurgical patients who received prophylactic antibiotics consistent with \ncurrent guidelines (specific to each type of surgical procedure).\n
\n
\n", "
Individual Characteristic
\n", "
172
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Healthy Term Newborn", "
CMS185v2
\n", "
2
\n", "
Healthy Term Newborn
\n", "
California Maternal Quality Care Collaborative (CMQCC)
\n", "
California Maternal Quality Care Collaborative (CMQCC)
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
ff796fd9-f99d-41fd-b8c2-57d0a59a5d8d
\n", "
0716
\n", "
\nPercent of term singleton live births (excluding those with diagnoses originating \nin the fetal period) who DO NOT have significant complications during birth \nor the nursery care.\n
\n
\n", "
Procedure
\n", "
185
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero", "
CMS178v4
\n", "
4
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
d78ce034-8288-4012-a31e-7f485a74f2a9
\n", "
0453
\n", "
\nSurgical patients with urinary catheter removed on Postoperative Day 1 \nor Postoperative Day 2 with day of surgery being day zero.\n
\n
\n", "
Individual Characteristic
\n", "
178
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver", "
CMS26v2
\n", "
2
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nLOINC(R) is a registered trademark of the Regenstrief Institute.\n
\n
\n", "
\n
\n\n
\n", "
e1cb05e0-97d5-40fc-b456-15c5dbf44309
\n", "", "
\nAn assessment that there is documentation in the medical record that a \nHome Management Plan of Care (HMPC) document was given to the pediatric \nasthma patient/caregiver.\n
\n
\n", "
Individual Characteristic
\n", "
26
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision", "
CMS171v5
\n", "
5.0.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute. This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2014 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
d09add1d-30f5-462d-b677-3d17d9ccd664
\n", "
0527
\n", "
\nSurgical patients with prophylactic antibiotics initiated within one hour \nprior to surgical incision. Patients who received vancomycin or a fluoroquinolone \nfor prophylactic antibiotics should have the antibiotics initiated within \ntwo hours prior to surgical incision. Due to the longer infusion time required \nfor vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics \nwithin two hours prior to incision time.\n
\n
\n", "
Procedure
\n", "
171
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero", "
CMS178v5
\n", "
5.0.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2014 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
d78ce034-8288-4012-a31e-7f485a74f2a9
\n", "
0453
\n", "
\nSurgical patients with urinary catheter removed on Postoperative Day 1 \nor Postoperative Day 2 with day of surgery being day zero.\n
\n
\n", "
Procedure
\n", "
178
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["HIV/AIDS: RNA Control for Patients with HIV", "
CMS77v4
\n", "
4.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets. NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications. \nCPT(R) contained in the Measure specifications is copyright 2004-2014 American \nMedical Association. LOINC(R) copyright 2004-2014 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2014 International Health Terminology Standards Development Organisation.\n
\n
\n", "
\n
\n\n
\n", "
e0a07809-7b74-473f-bcc4-1891be506aaa
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, \nwith at least two visits during the measurement year, with at least 90 \ndays between each visit, whose most recent HIV RNA level is <200 copies/mL.\n
\n
\n", "
Individual Characteristic
\n", "
77
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Statin Prescribed at Discharge", "
CMS30v4
\n", "
4
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
ebfa203e-acc1-4228-906c-855c4bf11310
\n", "
0639
\n", "
\nAcute myocardial infarction (AMI) patients who are prescribed a statin \nat hospital discharge.\n
\n
\n", "
Individual Characteristic
\n", "
30
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Statin Prescribed at Discharge", "
CMS30v5
\n", "
5.0.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain LOINC(R) is a registered \ntrademark of the Regenstrief Institute. This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2014 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
ebfa203e-acc1-4228-906c-855c4bf11310
\n", "
0639
\n", "
\nAcute myocardial infarction (AMI) patients who are prescribed a statin \nmedication at hospital discharge.\n
\n
\n", "
Medication
\n", "
30
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["HIV/AIDS: Medical Visit", "
CMS62v4
\n", "
4.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nCopyright 2014 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
f70b2984-af4a-4072-ae0d-cec677a7ff8f
\n", "
Not Applicable
\n", "
\nPercentage of patients, regardless of age, with a diagnosis of HIV/AIDS \nwith at least two medical visits during the measurement year with a minimum \nof 90 days between each visit\n
\n
\n", "
Individual Characteristic
\n", "
62
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Elective Delivery", "
CMS113v4
\n", "
4.0.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(c)) copyright 2004-2014 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
fd7ca18d-b56d-4bca-af35-71ce36b15246
\n", "
0469
\n", "
\nPatients with elective vaginal deliveries or elective cesarean births at \n>= 37 and < 39 weeks of gestation completed\n
\n
\n", "
Condition/Diagnosis/Problem
\n", "
113
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Prophylactic Antibiotic Selection for Surgical Patients", "
CMS172v5
\n", "
5.0.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2014 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
feea3922-f61f-4b05-98f9-b72a11815f12
\n", "
0528
\n", "
\nSurgical patients who received prophylactic antibiotics consistent with \ncurrent guidelines (specific to each type of surgical procedure).\n
\n
\n", "
Procedure
\n", "
172
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Intensive Care Unit Venous Thromboembolism Prophylaxis", "
CMS190v3
\n", "
3
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
fa91ba68-1e66-4a23-8eb2-baa8e6df2f2f
\n", "
0372
\n", "
\nThis measure assesses the number of patients who received VTE prophylaxis \nor have documentation why no VTE prophylaxis was given the day of or the \nday after the initial admission (or transfer) to the Intensive Care Unit \n(ICU) or surgery end date for surgeries that start the day of or the day \nafter ICU admission (or transfer).\n
\n
\n", "
Individual Characteristic
\n", "
190
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Venous Thromboembolism Prophylaxis", "
CMS108v5
\n", "
5.0.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
38b0b5ec-0f63-466f-8fe3-2cd20ddd1622
\n", "
0371
\n", "
\nThis measure assesses the number of patients who received VTE prophylaxis \nor have documentation why no VTE prophylaxis was given the day of or the \nday after hospital admission or surgery end date for surgeries that start \nthe day of or the day after hospital admission\n
\n
\n", "
Medication
\n", "
108
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery", "
CMS133v5
\n", "
5.2.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
39e0424a-1727-4629-89e2-c46c2fbb3f5f
\n", "
0565
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of uncomplicated \ncataract who had cataract surgery and no significant ocular conditions \nimpacting the visual outcome of surgery and had best-corrected visual acuity \nof 20/40 or better (distance or near) achieved within 90 days following \nthe cataract surgery\n
\n
\n", "
Individual Characteristic
\n", "
133
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Pregnant women that had HBsAg testing", "
CMS158v5
\n", "
5.2.000
\n", "", "
Optum
\n", "
Optum
\n", "
\nThis measure is copyrighted by Optum, Inc.  All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
3bbfc929-50c8-44b8-8d34-82be75c08a70
\n", "
Not Applicable
\n", "
\nThis measure identifies pregnant women who had a HBsAg (hepatitis B) test \nduring their pregnancy\n
\n
\n", "
Individual Characteristic
\n", "
158
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Median Time from ED Arrival to ED Departure for Discharged ED Patients", "
CMS32v6
\n", "
6.1.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms(R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
3fd13096-2c8f-40b5-9297-b714e8de9133
\n", "
0496
\n", "
\nMedian elapsed time from emergency department arrival to emergency room \ndeparture for patients discharged from the emergency department\n
\n
\n", "
Individual Characteristic
\n", "
32
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Discharged on Antithrombotic Therapy", "
CMS104v5
\n", "
5.2.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
42bf391f-38a3-4c0f-9ece-dcd47e9609d9
\n", "
0435
\n", "
\nIschemic stroke patients prescribed antithrombotic therapy at hospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
104
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Cervical Cancer Screening", "
CMS124v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
42e7e489-790f-427a-a1a6-d6e807f65a6d
\n", "
0032
\n", "
\nPercentage of women 21-64 years of age who were screened for cervical cancer \nusing either of the following criteria:*  Women age 21-64 who had cervical \ncytology performed every 3 years*  Women age 30-64 who had cervical cytology/human \npapillomavirus (HPV) co-testing performed every 5 years\n
\n
\n", "
Individual Characteristic
\n", "
124
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)", "
CMS135v5
\n", "
5.2.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 American College of Cardiology, American Heart Association \nand American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
430ffc53-4122-4421-88cc-2edd8117bb3c
\n", "
2907
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of heart \nfailure (HF) with a current or prior left ventricular ejection fraction \n(LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within \na 12 month period when seen in the outpatient setting OR at each hospital \ndischarge\n
\n
\n", "
Individual Characteristic
\n", "
135
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Ischemic Vascular Disease (IVD): Complete Lipid Profile and LDL-C Control (<100 mg/dL)", "
CMS182v6
\n", "
6.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT [R]) copyright 2004-2015 International Health Terminology Standards \nDevelopment Organisation. ICD-10 copyright 2015 World Health Organization. \nwere developed by the National Committee for Quality Assurance (NCQA). \nAll Rights Reserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
500e4792-7f94-4e34-8546-ee71c56fe463
\n", "
Not Applicable
\n", "
\nPercentage of patients 18 years of age and older who were diagnosed with \nacute myocardial infarction (AMI), coronary artery bypass graft (CABG) \nor percutaneous coronary interventions (PCI) in the 12 months prior to \nthe measurement period, or who had a diagnosis of ischemic vascular disease \n(IVD) during the measurement period, and who had a complete lipid profile \nperformed during the measurement period and whose most recent Low-density \nLipoprotein (LDL-C) was adequately controlled (< 100 mg/dL)\n
\n
\n", "
Individual Characteristic
\n", "
182
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy", "
CMS167v5
\n", "
5.2.000
\n", "", "
PCPI(R) Foundation (PCPI[R])
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
50164228-9d64-4efc-af67-da0547ff61f1
\n", "
0088
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of diabetic \nretinopathy who had a dilated macular or fundus exam performed which included \ndocumentation of the level of severity of retinopathy and the presence \nor absence of macular edema during one or more office visits within 12 \nmonths\n
\n
\n", "
Individual Characteristic
\n", "
167
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care", "
CMS142v5
\n", "
5.2.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
53d6d7c3-43fb-4d24-8099-17e74c022c05
\n", "
0089
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of diabetic \nretinopathy who had a dilated macular or fundus exam performed with documented \ncommunication to the physician who manages the ongoing care of the patient \nwith diabetes mellitus regarding the findings of the macular or fundus \nexam at least once within 12 months\n
\n
\n", "
Individual Characteristic
\n", "
142
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Elective Delivery", "
CMS113v3
\n", "
3
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
fd7ca18d-b56d-4bca-af35-71ce36b15246
\n", "
0469
\n", "
\nPatients with elective vaginal deliveries or elective cesarean sections \nat >= 37 and < 39 weeks of gestation completed\n
\n
\n", "
Individual Characteristic
\n", "
113
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Pneumococcal Vaccination Status for Older Adults", "
CMS127v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (c) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
59657b9b-01bf-4979-a090-8534da1d0516
\n", "
0043
\n", "
\nPercentage of patients 65 years of age and older who have ever received \na pneumococcal vaccine\n
\n
\n", "
Individual Characteristic
\n", "
127
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Use of Appropriate Medications for Asthma", "
CMS126v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
59e84144-6332-4369-aebd-03a7899ca3da
\n", "
Not Applicable
\n", "
\nPercentage of patients 5-64 years of age who were identified as having \npersistent asthma and were appropriately ordered medication during the \nmeasurement period\n
\n
\n", "
Individual Characteristic
\n", "
126
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Adult Major Depressive Disorder (MDD): Suicide Risk Assessment", "
CMS161v5
\n", "
5.0.000
\n", "", "
PCPI(R) Foundation (PCPI[R])
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
60176fbf-bfdc-4892-9c9e-604f206553c8
\n", "
0104
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of major \ndepressive disorder (MDD) with a suicide risk assessment completed during \nthe visit in which a new diagnosis or recurrent episode was identified\n
\n
\n", "
Individual Characteristic
\n", "
161
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Children Who Have Dental Decay or Cavities", "
CMS75v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets. NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications. \nCPT(R) contained in the Measure specifications is copyright 2004-2015 American \nMedical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2015 International Health Terminology Standards Development Organisation. \nICD-10 copyright 2015 World Health Organization. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
61947125-4376-4a7b-ab7a-ac2be9bd9138
\n", "
Not Applicable
\n", "
\nPercentage of children, age 0-20 years, who have had tooth decay or cavities \nduring the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
75
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Venous Thromboembolism Patients with Anticoagulation Overlap Therapy", "
CMS73v5
\n", "
5.1.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
6f069bb2-b3c4-4bf4-adc5-f6dd424a10b7
\n", "
0373
\n", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nwho received an overlap of parenteral (intravenous [IV] or subcutaneous \n[subcu]) anticoagulation and warfarin therapy. For patients who received \nless than five days of overlap therapy, they should be discharged on both \nmedications or have a reason for discontinuation of overlap therapy. Overlap \ntherapy should be administered for at least five days with an international \nnormalized ratio (INR) greater than or equal to 2 prior to discontinuation \nof the parenteral anticoagulation therapy, discharged on both medications \nor have a reason for discontinuation of overlap therapy.\n
\n
\n", "
Medication
\n", "
73
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication", "
CMS136v6
\n", "
6.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (c) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
703cc49b-b653-4885-80e8-245a057f5ae9
\n", "
0108
\n", "
\nPercentage of children 6-12 years of age and newly dispensed a medication \nfor attention-deficit/hyperactivity disorder (ADHD) who had appropriate \nfollow-up care.  Two rates are reported.  a. Percentage of children who \nhad one follow-up visit with a practitioner with prescribing authority \nduring the 30-Day Initiation Phase.b. Percentage of children who remained \non ADHD medication for at least 210 days and who, in addition to the visit \nin the Initiation Phase, had at least two additional follow-up visits with \na practitioner within 270 days (9 months) after the Initiation Phase ended.\n
\n
\n", "
Individual Characteristic
\n", "
136
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Medical Attention for Nephropathy", "
CMS134v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
7b2a9277-43da-4d99-9bee-6ac271a07747
\n", "
0062
\n", "
\nThe percentage of patients 18-75 years of age with diabetes who had a nephropathy \nscreening test or evidence of nephropathy during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
134
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Dementia: Cognitive Assessment", "
CMS149v5
\n", "
5.2.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
7c443b9b-1ad1-4467-b527-defc445701ff
\n", "
Not Applicable
\n", "
\nPercentage of patients, regardless of age, with a diagnosis of dementia \nfor whom an assessment of cognition is performed and the results reviewed \nat least once within a 12 month period\n
\n
\n", "
Individual Characteristic
\n", "
149
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Exclusive Breast Milk Feeding", "
CMS9v5
\n", "
5.1.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nLOINC(R) is a registered trademark of the Regenstrief Institute. This material \ncontains SNOMED Clinical Terms (R) (SNOMED CT[C]) copyright 2004-2015 International \nHealth Terminology Standards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
7d374c6a-3821-4333-a1bc-4531005d77b8
\n", "
0480
\n", "
\nPC-05 Exclusive breast milk feeding during the newborn's entire hospitalization\n
\n
\n", "
Attribute
\n", "
9
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Assessed for Rehabilitation", "
CMS102v5
\n", "
5.2.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004 - 2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
7dc26160-e615-4cc2-879c-75985189ec1a
\n", "
0441
\n", "
\nIschemic or hemorrhagic stroke patients who were assessed for rehabilitation \nservices\n
\n
\n", "
Procedure
\n", "
102
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Prophylactic Antibiotic Selection for Surgical Patients", "
CMS172v4
\n", "
4
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
feea3922-f61f-4b05-98f9-b72a11815f12
\n", "
0528
\n", "
\nSurgical patients who received prophylactic antibiotics consistent with \ncurrent guidelines (specific to each type of surgical procedure).\n
\n
\n", "
Individual Characteristic
\n", "
172
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Venous Thromboembolism Discharge Instructions", "
CMS110v5
\n", "
5.1.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms(R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
7fe69617-fa28-4305-a2b8-ceb6bcd9693d
\n", "
Not Applicable
\n", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nthat are discharged to home, home care, court/law enforcement or home on \nhospice care on warfarin with written discharge instructions that address \nall four criteria: compliance issues, dietary advice, follow-up monitoring, \nand information about the potential for adverse drug reactions/interactions.\n
\n
\n", "
Communication
\n", "
110
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)", "
CMS145v5
\n", "
5.2.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 American College of Cardiology, American Heart Association \nand American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
80744ae2-de81-4b16-a71d-69522eb865c5
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of coronary \nartery disease seen within a 12 month period who also have a prior MI or \na current or prior LVEF <40% who were prescribed beta-blocker therapy\n
\n
\n", "
Individual Characteristic
\n", "
145
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients", "
CMS188v6
\n", "
6.2.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain  CPT(R) is a trademark \nof the American Medical Association. Current Procedural Terminology. (CPT) \nis copyright 2015 American Medical Association. All rights reserved. No \nfee schedules, basic units, relative values, or related listings are included \nin CPT. The AMA assumes no liability for the data contained herein. Applicable \nFARS/DFARS restrictions apply to government use.  LOINC(R) is a registered \ntrademark of the Regenstrief Institute.  This material contains SNOMED \nClinical Terms (R) (SNOMED CT(C)) copyright 2004-2015 International Health \nTerminology Standards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
8243eae0-bbd7-4107-920b-fc3db04b9584
\n", "
0147
\n", "
\n(PN-6) Immunocompetent patients with Community-Acquired Pneumonia who receive \nan initial antibiotic regimen during the first 24 hours that is consistent \nwith current guidelines (Population 1) Immunocompetent ICU patients with \nCommunity-Acquired Pneumonia who receive an initial antibiotic regimen \nduring the first 24 hours that is consistent with current guidelines(Population \n2) Immunocompetent non-Intensive Care Unit (ICU) patients with Community-Acquired \nPneumonia who receive an initial antibiotic regimen during the first 24 \nhours that is consistent with current guidelines\n
\n
\n", "
Procedure
\n", "
188
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)", "
CMS144v5
\n", "
5.2.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 American College of Cardiology, American Heart Association \nand American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
8439f671-2932-4d4c-88ca-ea5faeacc89a
\n", "
2908
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of heart \nfailure (HF) with a current or prior left ventricular ejection fraction \n(LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 \nmonth period when seen in the outpatient setting OR at each hospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
144
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Depression Remission at Twelve Months", "
CMS159v5
\n", "
5.0.000
\n", "", "
MN Community Measurement
\n", "
MN Community Measurement
\n", "
\nCopyright MN Community Measurement, 2016. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
8455cd3e-dbb9-4e0c-8084-3ece4068fe94
\n", "
0710
\n", "
\nPatients age 18 and older with major depression or dysthymia and an initial \nPatient Health Questionnaire (PHQ-9) score greater than nine who demonstrate \nremission at twelve months (+/- 30 days after an index visit) defined as \na PHQ-9 score less than five. This measure applies to both patients with \nnewly diagnosed and existing depression whose current PHQ-9 score indicates \na need for treatment.\n
\n
\n", "
Individual Characteristic
\n", "
159
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients", "
CMS141v6
\n", "
6.1.000
\n", "", "
PCPI(R) Foundation (PCPI[R])
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 American Society of Clinical Oncology, National Comprehensive \nCancer Network Association and American Medical Association. All Rights \nReserved.\n
\n
\n", "
\n
\n\n
\n", "
8479f6d6-4200-4fd0-9438-30048ebe3e29
\n", "
0385
\n", "
\nPercentage of patients aged 18 through 80 years with AJCC Stage III colon \ncancer who are referred for adjuvant chemotherapy, prescribed adjuvant \nchemotherapy, or have previously received adjuvant chemotherapy within \nthe 12-month reporting period\n
\n
\n", "
Individual Characteristic
\n", "
141
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment", "
CMS177v5
\n", "
5.0.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
848d09de-7e6b-43c4-bedd-5a2957ccffe3
\n", "
1365
\n", "
\nPercentage of patient visits for those patients aged 6 through 17 years \nwith adiagnosis of major depressive disorder with an assessment for suicide \nrisk\n
\n
\n", "
Individual Characteristic
\n", "
177
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Primary PCI Received Within 90 Minutes of Hospital Arrival", "
CMS53v5
\n", "
5.4.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain.This material contains \nSNOMED Clinical Terms (R) (SNOMED CT(C)) copyright 2004-2015 International \nHealth Terminology Standards Development Organization. All rights reserved.LOINC \n(R) is a registered trademark of the Regenstrief Institute.\n
\n
\n", "
\n
\n\n
\n", "
84b9d0b5-0caf-4e41-b345-3492a23c2e9f
\n", "
0163
\n", "
\nAcute myocardial infarction (AMI) patients with ST-segment elevation on \nthe ECG closest to arrival time receiving primary PCI during the hospital \nstay with a time from hospital arrival to PCI of 90 minutes or less.\n
\n
\n", "
Procedure
\n", "
53
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Anti-depressant Medication Management", "
CMS128v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets.  NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
8924f2b3-ec06-4650-b634-d70a53dee577
\n", "
0105
\n", "
\nPercentage of patients 18 years of age and older who were treated with \nantidepressant medication, had a diagnosis of major depression, and who \nremained on an antidepressant medication treatment. Two rates are reported. \na. Percentage of patients who remained on an antidepressant medication \nfor at least 84 days (12 weeks). b. Percentage of patients who remained \non an antidepressant medication for at least 180 days (6 months).\n
\n
\n", "
Individual Characteristic
\n", "
128
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Maternal Depression Screening", "
CMS82v4
\n", "
4.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (c) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
8e6c8479-99fd-4949-b0ad-24fa60fe4201
\n", "
Not Applicable
\n", "
\nThe percentage of children who turned 6 months of age during the measurement \nyear, who had a face-to-face visit between the clinician and the child \nduring child's first 6 months, and who had a maternal depression screening \nfor the mother at least once between 0 and 6 months of life.\n
\n
\n", "
Individual Characteristic
\n", "
82
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed", "
CMS61v6
\n", "
6.0.000
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nOrganization. All Rights Reserved.Due to technical limitations, registered \ntrademarks are indicated by (R) or [R] and unregistered trademarks are \nindicated by (TM) or [TM].\nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R]) or other coding contained in the specifications.CPT (R) contained \nin the Measure specifications is copyright 2007- 2016 American Medical \nAssociation. LOINC (R) copyright 2004-2015 [2.54] Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms (R) (SNOMED CT [R]) copyright \n2004-2015 [2015-09] International Health Terminology Standards Development \n
\n
\n", "
\n
\n\n
\n", "
0a7f0278-a05c-40aa-94a4-70ec44f5c568
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 20 through 79 years whose risk factors have \nbeen assessed and a fasting LDL-C test has been performed.\n
\n
\n", "
Individual Characteristic
\n", "
61
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival", "
CMS60v5
\n", "
5.4.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain.LOINC (R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
909cf4b4-7a85-4abf-a1c7-cb597ed1c0b6
\n", "
Not Applicable
\n", "
\nAcute myocardial infarction (AMI) patients with ST-segment elevation on \nthe ECG closest to arrival time receiving fibrinolytic therapy during the \nhospital stay and having a time from hospital arrival to fibrinolysis of \n30 minutes or less.\n
\n
\n", "
Procedure
\n", "
60
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Antithrombotic Therapy By End of Hospital Day 2", "
CMS72v5
\n", "
5.1.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms(R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
93f3479f-75d8-4731-9a3f-b7749d8bcd37
\n", "
0438
\n", "
\nIschemic stroke patients administered antithrombotic therapy by the end \nof hospital day 2\n
\n
\n", "
Medication
\n", "
72
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Hemoglobin A1c Test for Pediatric Patients", "
CMS148v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved. Physician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
95fb767e-0cb2-4778-b5ff-6ba9a53fa28e
\n", "
Not Applicable
\n", "
\nPercentage of patients 5-17 years of age with diabetes with a Hemoglobin \nA1c (HbA1c) test during the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
148
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Median Admit Decision Time to ED Departure Time for Admitted Patients", "
CMS111v5
\n", "
5.1.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms(R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
979f21bd-3f93-4cdd-8273-b23dfe9c0513
\n", "
0497
\n", "
\nMedian time (in minutes) from admit decision time to time of discharge \nfrom the emergency department for emergency department patients admitted \nto inpatient status.\n
\n
\n", "
Individual Characteristic
\n", "
111
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan", "
CMS69v5
\n", "
5.0.000
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nOrganization. All Rights Reserved.Due to technical limitations, registered \ntrademarks are indicated by (R) or [R] and unregistered trademarks are \nindicated by (TM) or [TM].\nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R]) or other coding contained in the specifications.CPT (R) contained \nin the Measure specifications is copyright 2007- 2016 American Medical \nAssociation. LOINC (R) copyright 2004-2015 [2.54] Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms (R) (SNOMED CT [R]) copyright \n2004-2015 [2015-09] International Health Terminology Standards Development \n
\n
\n", "
\n
\n\n
\n", "
9a031bb8-3d9b-11e1-8634-00237d5bf174
\n", "
0421
\n", "
\nPercentage of patients aged 18 years and older with a BMI documented during \nthe current encounter or during the previous six months AND with a BMI \noutside of normal parameters, a follow-up plan is documented during the \nencounter or during the previous six months of the current encounter  Normal \nParameters:       Age 18 years and older BMI => 18.5 and < 25 kg/m2\n
\n
\n", "
Individual Characteristic
\n", "
69
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Screening for Depression and Follow-Up Plan", "
CMS2v6
\n", "
6.3.000
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nAll Rights Reserved.Due to technical limitations, registered trademarks \nare indicated by (R) or [R] and unregistered trademarks are indicated by \n(TM) or [TM].\nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R]) or other coding contained in the specifications.CPT (R) contained \nin the Measure specifications is copyright 2007-2016 American Medical Association. \nLOINC (R) copyright 2004-2015 [2.50] Regenstrief Institute, Inc. This material \ncontains SNOMED Clinical Terms (R) (SNOMED CT [R]) copyright 2004-2015 \n[2014-09] International Health Terminology Standards Development Organization. \n
\n
\n", "
\n
\n\n
\n", "
9a031e24-3d9b-11e1-8634-00237d5bf174
\n", "
0418
\n", "
\nPercentage of patients aged 12 years and older screened for depression \non the date of the encounter using an age appropriate standardized depression \nscreening tool AND if positive, a follow-up plan is documented on the date \nof the positive screen\n
\n
\n", "
Individual Characteristic
\n", "
2
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Documentation of Current Medications in the Medical Record", "
CMS68v6
\n", "
6.1.000
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nOrganization. All Rights Reserved.Due to technical limitations, registered \ntrademarks are indicated by (R) or [R] and unregistered trademarks are \nindicated by (TM) or [TM].\nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R]) or other coding contained in the specifications.CPT (R) contained \nin the Measure specifications is copyright 2007- 2016 American Medical \nAssociation. LOINC (R) copyright 2004-2015 [2.54] Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms (R) (SNOMED CT [R]) copyright \n2004-2015 [2015-09] International Health Terminology Standards Development \n
\n
\n", "
\n
\n\n
\n", "
9a032d9c-3d9b-11e1-8634-00237d5bf174
\n", "
0419
\n", "
\nPercentage of visits for patients aged 18 years and older for which the \neligible professional attests to documenting a list of current medications \nusing all immediate resources available on the date of the encounter.  \nThis list must include ALL known prescriptions, over-the-counters, herbals, \nand vitamin/mineral/dietary (nutritional) supplements AND must contain \nthe medications' name, dosage, frequency and route of administration.\n
\n
\n", "
Individual Characteristic
\n", "
68
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Oncology: Medical and Radiation - Pain Intensity Quantified", "
CMS157v5
\n", "
5.2.000
\n", "", "
PCPI(R) Foundation (PCPI[R])
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association. All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
9a0330d0-3d9b-11e1-8634-00237d5bf174
\n", "
0384
\n", "
\nPercentage of patient visits, regardless of patient age, with a diagnosis \nof cancer currently receiving chemotherapy or radiation therapy in which \npain intensity is quantified\n
\n
\n", "
Individual Characteristic
\n", "
157
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Median Time from ED Arrival to ED Departure for Admitted ED Patients", "
CMS55v5
\n", "
5.1.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms(R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
9a033274-3d9b-11e1-8634-00237d5bf174
\n", "
0495
\n", "
\nMedian time from emergency department admission to time of discharge from \nthe emergency room for patients admitted to the facility from the emergency \ndepartment\n
\n
\n", "
Individual Characteristic
\n", "
55
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures", "
CMS132v5
\n", "
5.2.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
9a0339c2-3d9b-11e1-8634-00237d5bf174
\n", "
0564
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of uncomplicated \ncataract who had cataract surgery and had any of a specified list of surgical \nprocedures in the 30 days following cataract surgery which would indicate \nthe occurrence of any of the following major complications: retained nuclear \nfragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, \nor wound dehiscence\n
\n
\n", "
Individual Characteristic
\n", "
132
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Discharged on Statin Medication", "
CMS105v3
\n", "
3
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
1f503318-bb8d-4b91-af63-223ae0a2328e
\n", "
0439
\n", "
\nIschemic stroke patients with LDL greater than or equal to 100 mg/dL, or \nLDL not measured, or who were on a lipid-lowering medication prior to hospital \narrival are prescribed statin medication at hospital discharge.\n
\n
\n", "
Individual Characteristic
\n", "
105
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Preventive Care and Screening: Risk-Stratified Cholesterol Fasting Low Density Lipoprotein (LDL-C)", "
CMS64v4
\n", "
4
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
0336a17b-7c2a-48fc-a657-e9b04269a4cc
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 20 through 79 years who had a fasting LDL-C \ntest performed and whose risk-stratified fasting LDL-C is at or below the \nrecommended LDL-C goal.\n
\n
\n", "
Individual Characteristic
\n", "
64
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented", "
CMS22v5
\n", "
5.1.000
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nOrganization. All Rights Reserved.Due to technical limitations, registered \ntrademarks are indicated by (R) or [R] and unregistered trademarks are \nindicated by (TM) or [TM].\nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R]) or other coding contained in the specifications.CPT (R) contained \nin the Measure specifications is copyright 2007- 2016 American Medical \nAssociation. LOINC (R) copyright 2004-2015 [2.54] Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms (R) (SNOMED CT [R]) copyright \n2004-2015 [2015-09] International Health Terminology Standards Development \n
\n
\n", "
\n
\n\n
\n", "
9a033a94-3d9b-11e1-8634-00237d5bf174
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 18 years and older seen during the reporting \nperiod who were screened for high blood pressure AND a recommended follow-up \nplan is documented based on the current blood pressure (BP) reading as \nindicated\n
\n
\n", "
Individual Characteristic
\n", "
22
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Influenza Immunization", "
CMS147v6
\n", "
6.1.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
a244aa29-7d11-4616-888a-86e376bfcc6f
\n", "
0041
\n", "
\nPercentage of patients aged 6 months and older seen for a visit between \nOctober 1 and March 31 who received an influenza immunization OR who reported \nprevious receipt of an influenza immunization\n
\n
\n", "
Individual Characteristic
\n", "
147
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Use of High-Risk Medications in the Elderly", "
CMS156v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
a3837ff8-1abc-4ba9-800e-fd4e7953adbd
\n", "
0022
\n", "
\nPercentage of patients 66 years of age and older who were ordered high-risk \nmedications. Two rates are reported.a. Percentage of patients who were \nordered at least one high-risk medication. b. Percentage of patients who \nwere ordered at least two different high-risk medications.\n
\n
\n", "
Individual Characteristic
\n", "
156
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Depression Utilization of the PHQ-9 Tool", "
CMS160v5
\n", "
5.0.000
\n", "", "
MN Community Measurement
\n", "
MN Community Measurement
\n", "
\nCopyright MN Community Measurement, 2016. All rights reserved\n
\n
\n", "
\n
\n\n
\n", "
a4b9763c-847e-4e02-bb7e-acc596e90e2c
\n", "
0712
\n", "
\nPatients age 18 and older with the diagnosis of major depression or dysthymia \nwho have a Patient Health Questionnaire (PHQ-9) tool administered at least \nonce during a 4-month period in which there was a qualifying visit\n
\n
\n", "
Individual Characteristic
\n", "
160
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range", "
CMS179v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets. NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications. \nCPT(R) contained in the Measure specifications is copyright 2004-2015 American \nMedical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2015 International Health Terminology Standards Development Organisation. \nICD-10 copyright 2015 World Health Organization. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
a5e96a45-8132-4e72-bf4f-e8c81db9e641
\n", "
Not Applicable
\n", "
\nAverage percentage of time in which patients aged 18 and older with atrial \nfibrillation who are on chronic warfarin therapy have International Normalized \nRatio (INR) test results within the therapeutic range (i.e., TTR) during \nthe measurement period.\n
\n
\n", "
Medication
\n", "
179
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Colorectal Cancer Screening", "
CMS130v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
aa2a4bbc-864f-45ee-b17a-7ebcc62e6aac
\n", "
0034
\n", "
\nPercentage of adults 50-75 years of age who had appropriate screening for \ncolorectal cancer.\n
\n
\n", "
Individual Characteristic
\n", "
130
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Controlling High Blood Pressure", "
CMS165v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
abdc37cc-bac6-4156-9b91-d1be2c8b7268
\n", "
0018
\n", "
\nPercentage of patients 18-85 years of age who had a diagnosis of hypertension \nand whose blood pressure was adequately controlled (<140/90mmHg) during \nthe measurement period\n
\n
\n", "
Individual Characteristic
\n", "
165
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Breast Cancer: Hormonal Therapy for Stage I (T1b)-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer", "
CMS140v5
\n", "
5.0.000
\n", "", "
PCPI(R) Foundation (PCPI[R])
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 American Society of Clinical Oncology, National Comprehensive \nCancer Network Association and American Medical Association. All Rights \nReserved.\n
\n
\n", "
\n
\n\n
\n", "
ac639794-cb3f-4f4f-8fa6-680300d5ed4e
\n", "
0387
\n", "
\nPercentage of female patients aged 18 years and older with Stage I (T1b) \nthrough IIIC, ER or PR positive breast cancer who were prescribed tamoxifen \nor aromatase inhibitor (AI) during the 12-month reporting period\n
\n
\n", "
Individual Characteristic
\n", "
140
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Childhood Immunization Status", "
CMS117v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (c) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
b2802b7a-3580-4be8-9458-921aea62b78c
\n", "
0038
\n", "
\nPercentage of children 2 years of age who had four diphtheria, tetanus \nand acellular pertussis (DTaP); three polio (IPV), one measles, mumps and \nrubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); \none chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis \nA (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines \nby their second birthday\n
\n
\n", "
Individual Characteristic
\n", "
117
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Use of Imaging Studies for Low Back Pain", "
CMS166v6
\n", "
6.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
b6016b47-b65d-4be0-866f-1d397886ca89
\n", "
0052
\n", "
\nPercentage of patients 18-50 years of age with a diagnosis of low back \npain who did not have an imaging study (plain X-ray, MRI, CT scan) within \n28 days of the diagnosis.\n
\n
\n", "
Individual Characteristic
\n", "
166
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic", "
CMS164v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
0713ea8f-0e5b-4099-8c7c-dd677280398f
\n", "
0068
\n", "
\nPercentage of patients 18 years of age and older who were discharged alive \nfor acute myocardial infarction (AMI), coronary artery bypass graft (CABG) \nor percutaneous coronary interventions (PCI) in the 12 months prior to \nthe measurement period, or who had an active diagnosis of ischemic vascular \ndisease (IVD) during the measurement period, and who had documentation \nof use of aspirin or another antithrombotic during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
164
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use", "
CMS169v5
\n", "
5.0.000
\n", "", "
Center for Quality Assessment & Improvement in Mental Health (CQAIMH)
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nThis measure is copyrighted by CQAIMH.  It may be used for research, teaching, \nand quality measurement / improvement activities - provided the following:* \nThe materials are not sold, distributed or licensed for commercial purposes* \nCQAIMH's copyright is acknowledged in reproductions of these materials* \nModifications to the materials are not made without CQAIMH's permission\n
\n
\n", "
\n
\n\n
\n", "
b99aaef6-7889-4aba-85fc-5a2b739dd098
\n", "
Not Applicable
\n", "
\nPercentage of patients with depression or bipolar disorder with evidence \nof an initial assessment that includes an appraisal for alcohol or chemical \nsubstance use\n
\n
\n", "
Individual Characteristic
\n", "
169
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Aspirin Prescribed at Discharge", "
CMS100v5
\n", "
5.2.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain.LOINC (R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT (C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
bb481284-30dd-4383-928c-82385bbf1b17
\n", "
0142
\n", "
\nAcute myocardial infarction (AMI) patients who are prescribed aspirin at \nhospital discharge\n
\n
\n", "
Medication
\n", "
100
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Functional Status Assessments for Congestive Heart Failure", "
CMS90v6
\n", "
6.2.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.  NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications.CPT(R) \ncontained in the Measure specifications is copyright 2004-2015 American \nMedical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2015 International Health Terminology Standards Development Organisation. \nICD-10 copyright 2015 World Health Organization. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
bb9b8ef7-0354-40e0-bec7-d6891b7df519
\n", "
Not Applicable
\n", "
\nPercentage of patients 65 years of age and older with congestive  heart \nfailure who completed initial and follow-up patient-reported functional \nstatus assessments\n
\n
\n", "
Individual Characteristic
\n", "
90
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Falls: Screening for Future Fall Risk", "
CMS139v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nCopyright 2015 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
bc5b4a57-b964-4399-9d40-667c896f31ea
\n", "
0101
\n", "
\nPercentage of patients 65 years of age and older who were screened for \nfuture fall risk during the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
139
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Venous Thromboembolism Patients Receiving Unfractionated Heparin with Dosages/Platelet Count Monitoring by Protocol or Nomogram", "
CMS109v5
\n", "
5.1.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms(R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
bcce43dd-08e3-46c3-bfdd-0b1b472690f0
\n", "
Not Applicable
\n", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nwho received intravenous (IV) UFH therapy dosages AND had their platelet \ncounts monitored using defined parameters such as a nomogram or protocol.\n
\n
\n", "
Attribute
\n", "
109
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Functional Status Assessment for Total Knee Replacement", "
CMS66v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets. NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications. \nCPT(R) contained in the Measure specifications is copyright 2004-2015 American \nMedical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2015 International Health Terminology Standards Development Organisation. \nICD-10 copyright 2015 World Health Organization. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
be8d9655-1194-46ef-b43e-4b1d0c36ab71
\n", "
Not Applicable
\n", "
\nPercentage of patients 18 years of age and older with primary total knee \narthroplasty (TKA) who completed baseline and follow-up patient-reported \nfunctional status assessments\n
\n
\n", "
Individual Characteristic
\n", "
66
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Appropriate Testing for Children with Pharyngitis", "
CMS146v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (c) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
beb1c33c-2549-4e7f-9567-05ed38448464
\n", "
Not Applicable
\n", "
\nPercentage of children 3-18 years of age who were diagnosed with pharyngitis, \nordered an antibiotic and received a group A streptococcus (strep) test \nfor the episode\n
\n
\n", "
Individual Characteristic
\n", "
146
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Foot Exam", "
CMS123v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \n Reserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
c0d72444-7c26-4863-9b51-8080f8928a85
\n", "
0056
\n", "
\nThe percentage of patients 18-75 years of age with diabetes (type 1 and \ntype 2) who received a foot exam (visual inspection and sensory exam with \nmono filament and a pulse exam) during the measurement year\n
\n
\n", "
Individual Characteristic
\n", "
123
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Initiation and Engagement of Alcohol and Other Drug Dependence Treatment", "
CMS137v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
c3657d72-21b4-4675-820a-86c7fe293bf5
\n", "
0004
\n", "
\nPercentage of patients 13 years of age and older with a new episode of \nalcohol and other drug (AOD) dependence who received the following. Two \nrates are reported.a. Percentage of patients who initiated treatment within \n14 days of the diagnosis.b. Percentage of patients who initiated treatment \nand who had two or more additional services with an AOD diagnosis within \n30 days of the initiation visit.\n
\n
\n", "
Individual Characteristic
\n", "
137
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Chlamydia Screening for Women", "
CMS153v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (c) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
c9930664-be3d-4ffe-ae4a-5cf4933ecb89
\n", "
0033
\n", "
\nPercentage of women 16-24 years of age who were identified as sexually \nactive and who had at least one test for chlamydia during the measurement \nperiod\n
\n
\n", "
Individual Characteristic
\n", "
153
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed", "
CMS61v4
\n", "
4
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
0a7f0278-a05c-40aa-94a4-70ec44f5c568
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 20 through 79 years whose risk factors have \nbeen assessed and a fasting LDL-C test has been performed.\n
\n
\n", "
Individual Characteristic
\n", "
61
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision", "
CMS171v6
\n", "
6.3.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute. This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
d09add1d-30f5-462d-b677-3d17d9ccd664
\n", "
0527
\n", "
\nSurgical patients with prophylactic antibiotics initiated within one hour \nprior to surgical incision. Patients who received vancomycin or a fluoroquinolone \nfor prophylactic antibiotics should have the antibiotics initiated within \ntwo hours prior to surgical incision. Due to the longer infusion time required \nfor vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics \nwithin two hours prior to incision time.\n
\n
\n", "
Procedure
\n", "
171
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero", "
CMS178v6
\n", "
6.4.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
d78ce034-8288-4012-a31e-7f485a74f2a9
\n", "
Not Applicable
\n", "
\nSurgical patients with urinary catheter removed on Postoperative Day 1 \nor Postoperative Day 2 with day of surgery being day zero\n
\n
\n", "
Procedure
\n", "
178
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Diabetes: Eye Exam", "
CMS131v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
d90bdab4-b9d2-4329-9993-5c34e2c0dc66
\n", "
0055
\n", "
\nPercentage of patients 18-75 years of age with diabetes who had a retinal \nor dilated eye exam by an eye care professional during the measurement \nperiod or a negative retinal exam (no evidence of retinopathy) in the 12 \nmonths prior to the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
131
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation", "
CMS143v5
\n", "
5.2.000
\n", "", "
American Medical Association (AMA)
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
db9d9f09-6b6a-4749-a8b2-8c1fdb018823
\n", "
0086
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of primary \nopen-angle glaucoma (POAG) who have an optic nerve head evaluation during \none or more office visits within 12 months\n
\n
\n", "
Individual Characteristic
\n", "
143
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["HIV/AIDS: RNA Control for Patients with HIV", "
CMS77v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets. NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications. \nCPT(R) contained in the Measure specifications is copyright 2004-2015 American \nMedical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2015 International Health Terminology Standards Development Organisation. \nICD-10 copyright 2015 World Health Organization. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
e0a07809-7b74-473f-bcc4-1891be506aaa
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 13 years and older with a diagnosis of HIV/AIDS, \nwith at least two visits during the measurement year, with at least 90 \ndays between each visit, whose most recent HIV RNA level is <200 copies/mL\n
\n
\n", "
Individual Characteristic
\n", "
77
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver", "
CMS26v4
\n", "
4.2.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nLOINC(R) is a registered trademark of the Regenstrief Institute.This material \ncontains SNOMED Clinical Terms (R) (SNOMED CT(C)) copyright 2004-2015 International \nHealth Terminology Standards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
e1cb05e0-97d5-40fc-b456-15c5dbf44309
\n", "
Not Applicable
\n", "
\nAn assessment that there is documentation in the medical record that a \nHome Management Plan of Care (HMPC) document was given to the pediatric \nasthma patient/caregiver\n
\n
\n", "
Individual Characteristic
\n", "
26
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention", "
CMS138v5
\n", "
5.0.000
\n", "", "
PCPI(R) Foundation (PCPI[R])
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
e35791df-5b25-41bb-b260-673337bc44a8
\n", "
0028
\n", "
\nPercentage of patients aged 18 years and older who were screened for tobacco \nuse one or more times within 24 months AND who received cessation counseling \nintervention if identified as a tobacco user\n
\n
\n", "
Individual Characteristic
\n", "
138
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Appropriate Treatment for Children with Upper Respiratory Infection (URI)", "
CMS154v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
e455fac0-f2cb-4074-a351-1e68a90fb7cf
\n", "
0069
\n", "
\nPercentage of children 3 months-18 years of age who were diagnosed with \nupper respiratory infection (URI) and were not dispensed an antibiotic \nprescription on or three days after the episode\n
\n
\n", "
Individual Characteristic
\n", "
154
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Statin Prescribed at Discharge", "
CMS30v6
\n", "
6.2.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public Domain LOINC(R) is a registered \ntrademark of the Regenstrief Institute. This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
ebfa203e-acc1-4228-906c-855c4bf11310
\n", "
Not Applicable
\n", "
\nAcute myocardial infarction (AMI) patients who are prescribed a statin \nmedication at hospital discharge\n
\n
\n", "
Medication
\n", "
30
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)", "
CMS122v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
f2986519-5a4e-4149-a8f2-af0a1dc7f6bc
\n", "
0059
\n", "
\nPercentage of patients 18-75 years of age with diabetes who had hemoglobin \nA1c > 9.0% during the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
122
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents", "
CMS155v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
0b63f730-25d6-4248-b11f-8c09c66a04eb
\n", "
0024
\n", "
\nPercentage of patients 3-17 years of age who had an outpatient visit with \na Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and \nwho had evidence of the following during the measurement period. Three \nrates are reported. - Percentage of patients with height, weight, and body \nmass index (BMI) percentile documentation - Percentage of patients with \ncounseling for nutrition - Percentage of patients with counseling for physical \nactivity\n
\n
\n", "
Individual Characteristic
\n", "
155
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Closing the Referral Loop: Receipt of Specialist Report", "
CMS50v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets. NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications. \nCPT(R) contained in the Measure specifications is copyright 2004-2015 American \nMedical Association. LOINC(R) is copyright 2004-2015 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2015 International Health Terminology Standards Development Organisation.\n
\n
\n", "
\n
\n\n
\n", "
f58fc0d6-edf5-416a-8d29-79afbfd24dea
\n", "
Not Applicable
\n", "
\nPercentage of patients with referrals, regardless of age, for which the \nreferring provider receives a report from the provider to whom the patient \nwas referred\n
\n
\n", "
Individual Characteristic
\n", "
50
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["HIV/AIDS: Medical Visit", "
CMS62v5
\n", "
5.3.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nCopyright 2015 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
f70b2984-af4a-4072-ae0d-cec677a7ff8f
\n", "
Not Applicable
\n", "
\nPercentage of patients, regardless of age, with a diagnosis of HIV/AIDS \nwith at least two medical visits during the measurement year with a minimum \nof 90 days between each visit\n
\n
\n", "
Individual Characteristic
\n", "
62
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Intensive Care Unit Venous Thromboembolism Prophylaxis", "
CMS190v5
\n", "
5.2.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.  This material contains SNOMED \nClinical Terms(R) (SNOMED CT[C]) copyright 2004-2015 International Health \nTerminology Standards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
fa91ba68-1e66-4a23-8eb2-baa8e6df2f2f
\n", "
0372
\n", "
\nThis measure assesses the number of patients who received VTE prophylaxis \nor have documentation why no VTE prophylaxis was given the day of or the \nday after the initial admission (or transfer) to the Intensive Care Unit \n(ICU) or surgery end date for surgeries that start the day of or the day \nafter ICU admission (or transfer)\n
\n
\n", "
Medication
\n", "
190
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Elective Delivery", "
CMS113v5
\n", "
5.1.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(c)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
fd7ca18d-b56d-4bca-af35-71ce36b15246
\n", "
0469
\n", "
\nPatients with elective vaginal deliveries or elective cesarean births at \n>= 37 and < 39 weeks of gestation completed\n
\n
\n", "
Condition/Diagnosis/Problem
\n", "
113
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Prophylactic Antibiotic Selection for Surgical Patients", "
CMS172v6
\n", "
6.2.000
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
feea3922-f61f-4b05-98f9-b72a11815f12
\n", "
0528
\n", "
\nSurgical patients who received prophylactic antibiotics consistent with \ncurrent guidelines (specific to each type of surgical procedure)\n
\n
\n", "
Procedure
\n", "
172
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Healthy Term Newborn", "
CMS185v5
\n", "
5.1.000
\n", "", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nMeasure specifications are in the Public DomainCPT(R) is a trademark of \nthe American Medical Association. Current Procedural Terminology. (CPT) \nis copyright 2015 American Medical Association. All rights reserved. No \nfee schedules, basic units, relative values, or related listings are included \nin CPT. The AMA assumes no liability for the data contained herein. Applicable \nFARS/DFARS restrictions apply to government use.LOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
ff796fd9-f99d-41fd-b8c2-57d0a59a5d8d
\n", "
0716
\n", "
\nPercent of term singleton live births (excluding those with diagnoses originating \nin the fetal period) who DO NOT have significant complications during birth \nor the nursery care\n
\n
\n", "
Procedure
\n", "
185
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists", "
CMS74v4
\n", "
4
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.\n
\n
\n", "
\n
\n\n
\n", "
0b81b6ba-3b30-41bf-a2f3-95bdc9f558f2
\n", "
Not Applicable
\n", "
\nPercentage of children, age 0-20 years, who received a fluoride varnish \napplication during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
74
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Low Density Lipoprotein (LDL) Management", "
CMS163v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
0dac1dec-e011-493b-a281-7c28964872dd
\n", "
0064
\n", "
\nPercentage of patients 1875 years of age with diabetes whose LDL-C was \nadequately controlled (<100 mg/dL) during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
163
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Weight Assessment and Counseling for Nutrition and Physical Activity for Children and Adolescents", "
CMS155v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
0b63f730-25d6-4248-b11f-8c09c66a04eb
\n", "
0024
\n", "
\nPercentage of patients 3-17 years of age who had an outpatient visit with \na Primary Care Physician (PCP) or Obstetrician/Gynecologist (OB/GYN) and \nwho had evidence of the following during the measurement period. Three \nrates are reported. - Percentage of patients with height, weight, and body \nmass index (BMI) percentile documentation - Percentage of patients with \ncounseling for nutrition - Percentage of patients with counseling for physical \nactivity\n
\n
\n", "
Individual Characteristic
\n", "
155
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Breast Cancer Screening", "
CMS125v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
19783c1b-4fd1-46c1-8a96-a2f192b97ee0
\n", "
Not Applicable
\n", "
\nPercentage of women 4069 years of age who had a mammogram to screen for \nbreast cancer.\n
\n
\n", "
Individual Characteristic
\n", "
125
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis", "
CMS52v3
\n", "
3
\n", "", "
National Committee for Quality Assurance/ and American Medical Association - convened Physician Consortium for Performance Improvement (AMA-PCPI)
\n", "
National Committee for Quality Assurance
\n", "
\nCopyright 2013 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
1cdd20de-5de9-4759-8a93-31f1f8baaaa2
\n", "
0405
\n", "
\nPercentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS \nwho were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis\n
\n
\n", "
Individual Characteristic
\n", "
52
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Hypertension: Improvement in Blood Pressure", "
CMS65v4
\n", "
4
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.\n
\n
\n", "
\n
\n\n
\n", "
1d8363ce-a529-490b-8c98-9b54aa75da06
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 18-85 years of age with a diagnosis of hypertension \nwhose blood pressure improved during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
65
\n", "
InProgress
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Stroke Education", "
CMS107v3
\n", "
3
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
217fdf0d-3d64-4720-9116-d5e5afa27f2c
\n", "", "
\nIschemic or hemorrhagic stroke patients or their caregivers who were given \neducational materials during the hospital stay addressing all of the following: \nactivation of emergency medical system, need for follow-up after discharge, \nmedications prescribed at discharge, risk factors for stroke, and warning \nsigns and symptoms of stroke.\n
\n
\n", "
Individual Characteristic
\n", "
107
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Functional Status Assessment for Hip Replacement", "
CMS56v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.  NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications.\n
\n
\n", "
\n
\n\n
\n", "
2f291003-3f2f-48af-bef9-e5aacb95ac3e
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 18 years and older with primary total hip arthroplasty \n(THA) who completed baseline and follow-up (patient-reported) functional \nstatus assessments\n
\n
\n", "
Individual Characteristic
\n", "
56
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Cataracts: 20/40 or Better Visual Acuity within 90 Days Following Cataract Surgery", "
CMS133v3
\n", "
3
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
39e0424a-1727-4629-89e2-c46c2fbb3f5f
\n", "
0565
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of uncomplicated \ncataract who had cataract surgery and no significant ocular conditions \nimpacting the visual outcome of surgery and had best-corrected visual acuity \nof 20/40 or better (distance or near) achieved within 90 days following \nthe cataract surgery\n
\n
\n", "
Individual Characteristic
\n", "
133
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Pregnant women that had HBsAg testing", "
CMS158v3
\n", "
3
\n", "", "
OptumInsight
\n", "
OptumInsight
\n", "
\n(C) 2014 Optum, Inc.  All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
3bbfc929-50c8-44b8-8d34-82be75c08a70
\n", "
Not Applicable
\n", "
\nThis measure identifies pregnant women who had a HBsAg (hepatitis B) test \nduring their pregnancy.\n
\n
\n", "
Individual Characteristic
\n", "
158
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Cervical Cancer Screening", "
CMS124v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
42e7e489-790f-427a-a1a6-d6e807f65a6d
\n", "
0032
\n", "
\nPercentage of women 21-64 years of age, who received one or more Pap tests \nto screen for cervical cancer.\n
\n
\n", "
Individual Characteristic
\n", "
124
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)", "
CMS135v3
\n", "
3
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 American College of Cardiology, American Heart Association \nand American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
430ffc53-4122-4421-88cc-2edd8117bb3c
\n", "
0081
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of heart \nfailure (HF) with a current or prior left ventricular ejection fraction \n(LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within \na 12 month period when seen in the outpatient setting OR at each hospital \ndischarge\n
\n
\n", "
Individual Characteristic
\n", "
135
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Ischemic Vascular Disease (IVD): Complete Lipid Panel and LDL Control", "
CMS182v4
\n", "
4
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
500e4792-7f94-4e34-8546-ee71c56fe463
\n", "
0075
\n", "
\nPercentage of patients 18 years of age and older who were discharged alive \nfor acute myocardial infarction (AMI), coronary artery bypass graft (CABG) \nor percutaneous coronary interventions (PCI) in the 12 months prior to \nthe measurement period, or who had an active diagnosis of ischemic vascular \ndisease (IVD) during the measurement period, and who had a complete lipid \nprofile performed during the measurement period and whose LDL-C was adequately \ncontrolled (< 100 mg/dL).\n
\n
\n", "
Individual Characteristic
\n", "
182
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy", "
CMS167v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
50164228-9d64-4efc-af67-da0547ff61f1
\n", "
0088
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of diabetic \nretinopathy who had a dilated macular or fundus exam performed which included \ndocumentation of the level of severity of retinopathy and the presence \nor absence of macular edema during one or more office visits within 12 \nmonths\n
\n
\n", "
Individual Characteristic
\n", "
167
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care", "
CMS142v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
53d6d7c3-43fb-4d24-8099-17e74c022c05
\n", "
0089
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of diabetic \nretinopathy who had a dilated macular or fundus exam performed with documented \ncommunication to the physician who manages the ongoing care of the patient \nwith diabetes mellitus regarding the findings of the macular or fundus \nexam at least once within 12 months\n
\n
\n", "
Individual Characteristic
\n", "
142
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Pneumonia Vaccination Status for Older Adults", "
CMS127v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
59657b9b-01bf-4979-a090-8534da1d0516
\n", "
0043
\n", "
\nPercentage of patients 65 years of age and older who have ever received \na pneumococcal vaccine.\n
\n
\n", "
Individual Characteristic
\n", "
127
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Use of Appropriate Medications for Asthma", "
CMS126v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
59e84144-6332-4369-aebd-03a7899ca3da
\n", "
0036
\n", "
\nPercentage of patients 5-64 years of age who were identified as having \npersistent asthma and were appropriately prescribed medication during the \nmeasurement period.\n
\n
\n", "
Individual Characteristic
\n", "
126
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Thrombolytic Therapy", "
CMS91v4
\n", "
4
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
2838875a-07b5-4bf0-be04-c3eb99f53975
\n", "
0437
\n", "
\nAcute ischemic stroke patients who arrive at this hospital within 2 hours \nof time last known well and for whom IV t-PA was initiated at this hospital \nwithin 3 hours of time last known well.\n
\n
\n", "
Medication
\n", "
91
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Adult Major Depressive Disorder (MDD): Suicide Risk Assessment", "
CMS161v3
\n", "
3
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
60176fbf-bfdc-4892-9c9e-604f206553c8
\n", "
0104
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of major \ndepressive disorder (MDD) with a suicide risk assessment completed during \nthe visit in which a new diagnosis or recurrent episode was identified\n
\n
\n", "
Individual Characteristic
\n", "
161
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Children Who Have Dental Decay or Cavities", "
CMS75v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.\n
\n
\n", "
\n
\n\n
\n", "
61947125-4376-4a7b-ab7a-ac2be9bd9138
\n", "
Not Applicable
\n", "
\nPercentage of children, age 0-20 years, who have had tooth decay or cavities \nduring the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
75
\n", "
InProgress
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["ADHD: Follow-Up Care for Children Prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) Medication", "
CMS136v4
\n", "
4
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
703cc49b-b653-4885-80e8-245a057f5ae9
\n", "
0108
\n", "
\nPercentage of children 6-12 years of age and newly dispensed a medication \nfor attention-deficit/hyperactivity disorder (ADHD) who had appropriate \nfollow-up care.  Two rates are reported.  a. Percentage of children who \nhad one follow-up visit with a practitioner with prescribing authority \nduring the 30-Day Initiation Phase.b. Percentage of children who remained \non ADHD medication for at least 210 days and who, in addition to the visit \nin the Initiation Phase, had at least two additional follow-up visits with \na practitioner within 270 days (9 months) after the Initiation Phase ended.\n
\n
\n", "
Individual Characteristic
\n", "
136
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Urine Protein Screening", "
CMS134v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
7b2a9277-43da-4d99-9bee-6ac271a07747
\n", "
0062
\n", "
\nThe percentage of patients 18-75 years of age with diabetes who had a nephropathy \nscreening test or evidence of nephropathy during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
134
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Primary Caries Prevention Intervention as Offered by Primary Care Providers, including Dentists", "
CMS74v6
\n", "
6.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets. NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications. \nCPT(R) contained in the Measure specifications is copyright 2004-2015 American \nMedical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2015 International Health Terminology Standards Development Organisation. \nICD-10 copyright 2015 World Health Organization. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
0b81b6ba-3b30-41bf-a2f3-95bdc9f558f2
\n", "
Not Applicable
\n", "
\nPercentage of children, age 0-20 years, who received a fluoride varnish \napplication during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
74
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Coronary Artery Disease (CAD): Beta-Blocker TherapyPrior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF <40%)", "
CMS145v3
\n", "
3
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 American College of Cardiology, American Heart Association \nand American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
80744ae2-de81-4b16-a71d-69522eb865c5
\n", "
0070
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of coronary \nartery disease seen within a 12 month period who also have a prior MI or \na current or prior LVEF <40% who were prescribed beta-blocker therapy\n
\n
\n", "
Individual Characteristic
\n", "
145
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)", "
CMS144v3
\n", "
3
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 American College of Cardiology, American Heart Association \nand American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
8439f671-2932-4d4c-88ca-ea5faeacc89a
\n", "
0083
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of heart \nfailure (HF) with a current or prior left ventricular ejection fraction \n(LVEF) < 40% who were prescribed beta-blocker therapy either within a 12 \nmonth period when seen in the outpatient setting OR at each hospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
144
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Depression Remission at Twelve Months", "
CMS159v3
\n", "
3
\n", "", "
MN Community Measurement
\n", "
MN Community Measurement
\n", "
\nCopyright MN Community Measurement, 2014. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
8455cd3e-dbb9-4e0c-8084-3ece4068fe94
\n", "
0710
\n", "
\nAdult patients age 18 and older with major depression or dysthymia and \nan initial PHQ-9 score > 9 who demonstrate remission at twelve months defined \nas PHQ-9 score less than 5. This measure applies to both patients with \nnewly diagnosed and existing depression whose current PHQ-9 score indicates \na need for treatment\n
\n
\n", "
Individual Characteristic
\n", "
159
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Colon Cancer: Chemotherapy for AJCC Stage III Colon Cancer Patients", "
CMS141v4
\n", "
4
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 American Society of Clinical Oncology, National Comprehensive \nCancer Network Association and American Medical Association. All Rights \nReserved.\n
\n
\n", "
\n
\n\n
\n", "
8479f6d6-4200-4fd0-9438-30048ebe3e29
\n", "
0385
\n", "
\nPercentage of patients aged 18 through 80 years with AJCC Stage III colon \ncancer who are referred for adjuvant chemotherapy, prescribed adjuvant \nchemotherapy, or have previously received adjuvant chemotherapy within \nthe 12-month reporting period.\n
\n
\n", "
Individual Characteristic
\n", "
141
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment", "
CMS177v3
\n", "
3
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
848d09de-7e6b-43c4-bedd-5a2957ccffe3
\n", "
1365
\n", "
\nPercentage of patient visits for those patients aged 6 through 17 years \nwith adiagnosis of major depressive disorder with an assessment for suicide \nrisk\n
\n
\n", "
Individual Characteristic
\n", "
177
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Incidence of Potentially-Preventable Venous Thromboembolism", "
CMS114v3
\n", "
3
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
32cfc834-843a-4f45-b359-8e158eac4396
\n", "", "
\nThis measure assesses the number of patients diagnosed with confirmed VTE \nduring hospitalization (not present at admission) who did not receive VTE \nprophylaxis between hospital admission and the day before the VTE diagnostic \ntesting order date.\n
\n
\n", "
Individual Characteristic
\n", "
114
\n", "
InProgress
\n", "
OUTCOME
\n", "
FY 2014 EH
\n"], ["Anti-depressant Medication Management", "
CMS128v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
8924f2b3-ec06-4650-b634-d70a53dee577
\n", "
0105
\n", "
\nPercentage of patients 18 years of age and older who were diagnosed with \nmajor depression and treated with antidepressant medication, and who remained \non antidepressant medication treatment. Two rates are reported. a. Percentage \nof patients who remained on an antidepressant medication for at least 84 \ndays (12 weeks). b. Percentage of patients who remained on an antidepressant \nmedication for at least 180 days (6 months).\n
\n
\n", "
Individual Characteristic
\n", "
128
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Maternal Depression Screening", "
CMS82v2
\n", "
2
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
8e6c8479-99fd-4949-b0ad-24fa60fe4201
\n", "
1401
\n", "
\nThe percentage of children who turned 6 months of age during the measurement \nyear, who had a face-to-face visit between the clinician and the child \nduring childs first 6 months, and who had a maternal depression screening \nfor the mother at least once between 0 and 6 months of life.\n
\n
\n", "
Individual Characteristic
\n", "
82
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Hemoglobin A1c Test for Pediatric Patients", "
CMS148v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
95fb767e-0cb2-4778-b5ff-6ba9a53fa28e
\n", "
0060
\n", "
\nPercentage of patients 5-17 years of age with diabetes with an HbA1c test \nduring the measurement period\n
\n
\n", "
Individual Characteristic
\n", "
148
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan", "
CMS69v3
\n", "
3
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
9a031bb8-3d9b-11e1-8634-00237d5bf174
\n", "
0421
\n", "
\nPercentage of patients aged 18 years and older with a BMI documented during \nthe current encounter or during the previous six months AND with a BMI \noutside of normal parameters, a follow-up plan is documented during the \nencounter or during the previous six months of the current encounter  Normal \nParameters:       Age 65 years and older BMI => 23 and < 30 kg/m2      \n                                Age 18  64 years BMI => 18.5 and < 25 kg/m2\n
\n
\n", "
Individual Characteristic
\n", "
69
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan", "
CMS2v4
\n", "
4
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
9a031e24-3d9b-11e1-8634-00237d5bf174
\n", "
0418
\n", "
\nPercentage of patients aged 12 years and older screened for clinical depression \non the date of the encounter using an age appropriate standardized depression \nscreening tool AND if positive, a follow-up plan is documented on the date \nof the positive screen.\n
\n
\n", "
Individual Characteristic
\n", "
2
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Diabetes: Low Density Lipoprotein (LDL-C) Control (< 100 mg/dL)", "
CMS163v5
\n", "
5.1.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
0dac1dec-e011-493b-a281-7c28964872dd
\n", "
Not Applicable
\n", "
\nPercentage of patients 18-75 years of age with diabetes whose LDL-C was \nadequately controlled (<100 mg/dL) during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
163
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Documentation of Current Medications in the Medical Record", "
CMS68v4
\n", "
4
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
9a032d9c-3d9b-11e1-8634-00237d5bf174
\n", "
0419
\n", "
\nPercentage of visits for patients aged 18 years and older for which the \neligible professional attests to documenting a list of current medications \nusing all immediate resources available on the date of the encounter.  \nThis list must include ALL known prescriptions, over-the-counters, herbals, \nand vitamin/mineral/dietary (nutritional) supplements AND must contain \nthe medications' name, dosage, frequency and route of administration.\n
\n
\n", "
Individual Characteristic
\n", "
68
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients", "
CMS129v6
\n", "
6.0.000
\n", "", "
PCPI(R) Foundation (PCPI[R])
\n", "
PCPI(R) Foundation (PCPI[R])
\n", "
\nCopyright 2015 PCPI(R) Foundation and American Medical Association.  All \nRights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
1635c14d-e612-4fa6-96cd-285361aa7f7b
\n", "
0389
\n", "
\nPercentage of patients, regardless of age, with a diagnosis of prostate \ncancer at low (or very low) risk of recurrence receiving interstitial prostate \nbrachytherapy, OR external beam radiotherapy to the prostate, OR radical \nprostatectomy, OR cryotherapy who did not have a bone scan performed at \nany time since diagnosis of prostate cancer\n
\n
\n", "
Individual Characteristic
\n", "
129
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Breast Cancer Screening", "
CMS125v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nof the Measures. (C) 2008-2016 National Committee for Quality Assurance. \nAll Rights Reserved. Limited proprietary coding is contained in the Measure \nspecifications for user convenience. Users of proprietary code sets should \nobtain all necessary licenses from the owners of the code sets. NCQA disclaims \nall liability for use or accuracy of any CPT or other codes contained in \nthe specifications.CPT(R) contained in the Measure specifications is copyright \n2004-2015 American Medical Association. LOINC(R) copyright 2004-2015 Regenstrief \nInstitute, Inc. This material contains SNOMED Clinical Terms(R) (SNOMED \nCT[R]) copyright 2004-2015 International Health Terminology Standards Development \nOrganisation. ICD-10 copyright 2015 World Health Organization. All Rights \nwere developed by the National Committee for Quality Assurance (NCQA). \nReserved.\nThe Measures are copyrighted but can be reproduced and distributed, without \nmodification, for noncommercial purposes (eg, use by healthcare providers \nin connection with their practices). Commercial use is defined as the sale, \nlicensing, or distribution of the Measures for commercial gain, or incorporation \nof the Measures into a product or service that is sold, licensed or distributed \nfor commercial gain. Commercial use of the Measures requires a license \nagreement between the user and NCQA. NCQA is not responsible for any use \n
\n
\n", "
\n
\n\n
\n", "
19783c1b-4fd1-46c1-8a96-a2f192b97ee0
\n", "
2372
\n", "
\nPercentage of women 50-74 years of age who had a mammogram to screen for \nbreast cancer\n
\n
\n", "
Individual Characteristic
\n", "
125
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis", "
CMS52v5
\n", "
5.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nCopyright 2015 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
1cdd20de-5de9-4759-8a93-31f1f8baaaa2
\n", "
0405
\n", "
\nPercentage of patients aged 6 weeks and older with a diagnosis of HIV/AIDS \nwho were prescribed Pneumocystis jiroveci pneumonia (PCP) prophylaxis\n
\n
\n", "
Individual Characteristic
\n", "
52
\n", "
COMPLETED
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Venous Thromboembolism Prophylaxis", "
CMS108v3
\n", "
3
\n", "", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
38b0b5ec-0f63-466f-8fe3-2cd20ddd1622
\n", "
0371
\n", "
\nThis measure assesses the number of patients who received VTE prophylaxis \nor have documentation why no VTE prophylaxis was given the day of or the \nday after hospital admission or surgery end date for surgeries that start \nthe day of or the day after hospital admission.\n
\n
\n", "
Individual Characteristic
\n", "
108
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Hypertension: Improvement in Blood Pressure", "
CMS65v6
\n", "
6.0.000
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services (CMS)
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets. NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications. \nCPT(R) contained in the Measure specifications is copyright 2004-2015 American \nMedical Association. LOINC(R) copyright 2004-2015 Regenstrief Institute, \nInc. This material contains SNOMED Clinical Terms(R) (SNOMED CT[R]) copyright \n2004-2015 International Health Terminology Standards Development Organisation. \nICD-10 copyright 2015 World Health Organization. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
1d8363ce-a529-490b-8c98-9b54aa75da06
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 18-85 years of age with a diagnosis of hypertension \nwhose blood pressure improved during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
65
\n", "
COMPLETED
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures", "
CMS132v3
\n", "
3
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
9a0339c2-3d9b-11e1-8634-00237d5bf174
\n", "
0564
\n", "
\nPercentage of patients aged 18 years and older with a diagnosis of uncomplicated \ncataract who had cataract surgery and had any of a specified list of surgical \nprocedures in the 30 days following cataract surgery which would indicate \nthe occurrence of any of the following major complications: retained nuclear \nfragments, endophthalmitis, dislocated or wrong power IOL, retinal detachment, \nor wound dehiscence\n
\n
\n", "
Individual Characteristic
\n", "
132
\n", "
Complete
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented", "
CMS22v3
\n", "
3
\n", "", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
9a033a94-3d9b-11e1-8634-00237d5bf174
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 18 years and older seen during the reporting \nperiod who were screened for high blood pressure AND a recommended follow-up \nplan is documented based on the current blood pressure (BP) reading as \nindicated\n
\n
\n", "
Individual Characteristic
\n", "
22
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Discharged on Statin Medication", "
CMS105v5
\n", "
5.3.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
1f503318-bb8d-4b91-af63-223ae0a2328e
\n", "
0439
\n", "
\nIschemic stroke patients who are prescribed statin medication at hospital \ndischarge\n
\n
\n", "
Medication
\n", "
105
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Preventive Care and Screening: Influenza Immunization", "
CMS147v4
\n", "
4
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 American Medical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
a244aa29-7d11-4616-888a-86e376bfcc6f
\n", "
0041
\n", "
\nPercentage of patients aged 6 months and older seen for a visit between \nOctober 1 and March 31 who received an influenza immunization OR who reported \nprevious receipt of an influenza immunization\n
\n
\n", "
Individual Characteristic
\n", "
147
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Use of High-Risk Medications in the Elderly", "
CMS156v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
a3837ff8-1abc-4ba9-800e-fd4e7953adbd
\n", "
0022
\n", "
\nPercentage of patients 66 years of age and older who were ordered high-risk \nmedications. Two rates are reported.a. Percentage of patients who were \nordered at least one high-risk medication. b. Percentage of patients who \nwere ordered at least two different high-risk medications.\n
\n
\n", "
Individual Characteristic
\n", "
156
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Stroke Education", "
CMS107v5
\n", "
5.1.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public DomainLOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT[C]) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
217fdf0d-3d64-4720-9116-d5e5afa27f2c
\n", "
Not Applicable
\n", "
\nIschemic or hemorrhagic stroke patients or their caregivers who were given \neducational materials during the hospital stay addressing all of the following: \nactivation of emergency medical system, need for follow-up after discharge, \nmedications prescribed at discharge, risk factors for stroke, and warning \nsigns and symptoms of stroke\n
\n
\n", "
Communication
\n", "
107
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Depression Utilization of the PHQ-9 Tool", "
CMS160v3
\n", "
3
\n", "", "
MN Community Measurement
\n", "
MN Community Measurement
\n", "
\nCopyright MN Community Measurement, 2014. All rights reserved\n
\n
\n", "
\n
\n\n
\n", "
a4b9763c-847e-4e02-bb7e-acc596e90e2c
\n", "
0712
\n", "
\nAdult patients age 18 and older with the diagnosis of major depression \nor dysthymia who have a PHQ-9 tool administered at least once during a \n4-month period in which there was a qualifying visit.\n
\n
\n", "
Individual Characteristic
\n", "
160
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Initial Antibiotic Selection for Community-Acquired Pneumonia (CAP) in Immunocompetent Patients", "
CMS188v1
\n", "
1
\n", "
PN 6
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
8243eae0-bbd7-4107-920b-fc3db04b9584
\n", "
0147
\n", "
\n(PN-6) Immunocompetent patients with Community-Acquired Pneumonia who receive \nan initial antibiotic regimen during the first 24 hours that is consistent \nwith current guidelines (Population 1) Immunocompetent ICU patients with \nCommunity-Acquired Pneumonia who receive an initial antibiotic regimen \nduring the first 24 hours that is consistent with current guidelines(Population \n2) Immunocompetent non-Intensive Care Unit (ICU) patients with Community-Acquired \nPneumonia who receive an initial antibiotic regimen during the first 24 \nhours that is consistent with current guidelines\n
\n
\n", "
Individual Characteristic
\n", "
188
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Primary PCI Received Within 90 Minutes of Hospital Arrival", "
CMS53v1
\n", "
1
\n", "
AMI-8a
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
84b9d0b5-0caf-4e41-b345-3492a23c2e9f
\n", "
0163
\n", "
\nAcute myocardial infarction (AMI) patients with ST-segment elevation or \nLBBB on the ECG closest to arrival time receiving primary PCI during the \nhospital stay with a time from hospital arrival to PCI of 90 minutes or \nless.\n
\n
\n", "
Individual Characteristic
\n", "
53
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Median Time from ED Arrival to ED Departure for Discharged ED Patients", "
CMS32v4
\n", "
4
\n", "", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nNone\n
\n
\n", "
\n
\n\n
\n", "
3fd13096-2c8f-40b5-9297-b714e8de9133
\n", "
0496
\n", "
\nMedian time from emergency department arrival to time of departure from \nthe emergency room for patients discharged from the emergency department.\n
\n
\n", "
Individual Characteristic
\n", "
32
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Fibrinolytic Therapy Received Within 30 Minutes of Hospital Arrival", "
CMS60v1
\n", "
1
\n", "
Fibrinolytic Therapy
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
909cf4b4-7a85-4abf-a1c7-cb597ed1c0b6
\n", "
0164
\n", "
\nAcute myocardial infarction (AMI) patients with ST-segment elevation or \nLBBB on the ECG closest to arrival time receiving fibrinolytic therapy \nduring the hospital stay and having a time from hospital arrival to fibrinolysis \nof 30 minutes or less\n
\n
\n", "
Individual Characteristic
\n", "
60
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Thrombolytic Therapy", "
CMS91v6
\n", "
6.1.000
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain.LOINC(R) is a registered \ntrademark of the Regenstrief Institute.This material contains SNOMED Clinical \nTerms (R) (SNOMED CT(C)) copyright 2004-2015 International Health Terminology \nStandards Development Organization. All rights reserved.\n
\n
\n", "
\n
\n\n
\n", "
2838875a-07b5-4bf0-be04-c3eb99f53975
\n", "
0437
\n", "
\nAcute ischemic stroke patients who arrive at this hospital within 2 hours \nof time last known well and for whom t-PA was initiated at this hospital \nwithin 3 hours of time last known well\n
\n
\n", "
Medication
\n", "
91
\n", "
COMPLETED
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["ADE Prevention and Monitoring: Warfarin Time in Therapeutic Range", "
CMS179v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.\n
\n
\n", "
\n
\n\n
\n", "
a5e96a45-8132-4e72-bf4f-e8c81db9e641
\n", "
NA
\n", "
\nAverage percentage of time in which patients aged 18 and older with atrial \nfibrillation who are on chronic warfarin therapy have International Normalized \nRatio (INR) test results within the therapeutic range (i.e., TTR) during \nthe measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
179
\n", "
InProgress
\n", "
OUTCOME
\n", "
CY 2014 EP
\n"], ["Colorectal Cancer Screening", "
CMS130v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
aa2a4bbc-864f-45ee-b17a-7ebcc62e6aac
\n", "
0034
\n", "
\nPercentage of adults 50-75 years of age who had appropriate screening for \ncolorectal cancer.\n
\n
\n", "
Individual Characteristic
\n", "
130
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Aspirin Prescribed at Discharge", "
CMS100v1
\n", "
1
\n", "
AMI-2
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
bb481284-30dd-4383-928c-82385bbf1b17
\n", "
0142
\n", "
\nAcute myocardial infarction (AMI) patients who are prescribed aspirin at \nhospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
100
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Controlling High Blood Pressure", "
CMS165v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
abdc37cc-bac6-4156-9b91-d1be2c8b7268
\n", "
0018
\n", "
\nPercentage of patients 18-85 years of age who had a diagnosis of hypertension \nand whose blood pressure was adequately controlled (<140/90mmHg) during \nthe measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
165
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Prophylactic Antibiotic Received Within One Hour Prior to Surgical Incision", "
CMS171v1
\n", "
1
\n", "
SCIP Prophylactic Antibiotic 1 H
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain.\n
\n
\n", "
\n
\n\n
\n", "
d09add1d-30f5-462d-b677-3d17d9ccd664
\n", "
0527
\n", "
\nSurgical patients with prophylactic antibiotics initiated within one hour \nprior to surgical incision. Patients who received vancomycin or a fluoroquinolone \nfor prophylactic antibiotics should have the antibiotics initiated within \ntwo hours prior to surgical incision. Due to the longer infusion time required \nfor vancomycin or a fluoroquinolone, it is acceptable to start these antibiotics \nwithin two hours prior to incision time.\n
\n
\n", "
Individual Characteristic
\n", "
171
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Urinary catheter removed on Postoperative Day 1 (POD 1) or Postoperative Day 2 (POD 2) with day of surgery being day zero", "
CMS178v1
\n", "
1
\n", "
Urinary catheter removed postop
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
d78ce034-8288-4012-a31e-7f485a74f2a9
\n", "
0453
\n", "
\nSurgical patients with urinary catheter removed on Postoperative Day 1 \nor Postoperative Day 2 with day of surgery being day zero.\n
\n
\n", "
Individual Characteristic
\n", "
178
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Home Management Plan of Care (HMPC) Document Given to Patient/Caregiver", "
CMS26v1
\n", "
1
\n", "
CAC-3
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nLOINC(R) is a registered trademark of the Regenstrief Institute.\n
\n
\n", "
\n
\n\n
\n", "
e1cb05e0-97d5-40fc-b456-15c5dbf44309
\n", "
0338
\n", "
\nAn assessment that there is documentation in the medical record that a \nHome Management Plan of Care (HMPC) document was given to the pediatric \nasthma patient/caregiver.\n
\n
\n", "
Individual Characteristic
\n", "
26
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Statin Prescribed at Discharge", "
CMS30v2
\n", "
2
\n", "
AMI-10
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Oklahoma Foundation for Medical Quality
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
ebfa203e-acc1-4228-906c-855c4bf11310
\n", "
0639
\n", "
\nAcute myocardial infarction (AMI) patients who are prescribed a statin \nat hospital discharge.\n
\n
\n", "
Individual Characteristic
\n", "
30
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Discharged on Antithrombotic Therapy", "
CMS104v3
\n", "
3
\n", "", "
The Joint Commission
\n", "
The Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
42bf391f-38a3-4c0f-9ece-dcd47e9609d9
\n", "
0435
\n", "
\nIschemic stroke patients prescribed antithrombotic therapy at hospital discharge\n
\n
\n", "
Individual Characteristic
\n", "
104
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer", "
CMS140v3
\n", "
3
\n", "", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
\nCopyright 2013 American Society of Clinical Oncology, National Comprehensive \nCancer Network Association and American Medical Association. All Rights \nReserved.\n
\n
\n", "
\n
\n\n
\n", "
ac639794-cb3f-4f4f-8fa6-680300d5ed4e
\n", "
0387
\n", "
\nPercentage of female patients aged 18 years and older with Stage IC through \nIIIC, ER or PR positive breast cancer who were prescribed tamoxifen or \naromatase inhibitor (AI) during the 12-month reporting period\n
\n
\n", "
Individual Characteristic
\n", "
140
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Elective Delivery", "
CMS113v1
\n", "
1
\n", "
Elective Delivery
\n", "
Joint Commission
\n", "
Joint Commission
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
fd7ca18d-b56d-4bca-af35-71ce36b15246
\n", "
0469
\n", "
\nPatients with elective vaginal deliveries or elective cesarean sections \nat >= 37 and < 39 weeks of gestation completed\n
\n
\n", "
Individual Characteristic
\n", "
113
\n", "
Complete
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Prophylactic Antibiotic Selection for Surgical Patients", "
CMS172v1
\n", "
1
\n", "
SCIP Antibiotic Selection
\n", "
Oklahoma Foundation for Medical Quality
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nMeasure specifications are in the Public Domain\n
\n
\n", "
\n
\n\n
\n", "
feea3922-f61f-4b05-98f9-b72a11815f12
\n", "
0528
\n", "
\nSurgical patients who received prophylactic antibiotics consistent with \ncurrent guidelines (specific to each type of surgical procedure).\n
\n
\n", "
Individual Characteristic
\n", "
172
\n", "
InProgress
\n", "
PROCESS
\n", "
FY 2014 EH
\n"], ["Childhood Immunization Status", "
CMS117v3
\n", "
3
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
b2802b7a-3580-4be8-9458-921aea62b78c
\n", "
0038
\n", "
\nPercentage of children 2 years of age who had four diphtheria, tetanus \nand acellular pertussis (DTaP); three polio (IPV), one measles, mumps and \nrubella (MMR); three H influenza type B (HiB); three hepatitis B (Hep B); \none chicken pox (VZV); four pneumococcal conjugate (PCV); one hepatitis \nA (Hep A); two or three rotavirus (RV); and two influenza (flu) vaccines \nby their second birthday.\n
\n
\n", "
Individual Characteristic
\n", "
117
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Risk-Stratified Cholesterol Fasting Low Density Lipoprotein (LDL-C)", "
CMS64v2
\n", "
2
\n", "
Cholesterol Screening B
\n", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
0336a17b-7c2a-48fc-a657-e9b04269a4cc
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 20 through 79 years who had a fasting LDL-C \ntest performed and whose risk-stratified fasting LDL-C is at or below the \nrecommended LDL-C goal.\n
\n
\n", "
Individual Characteristic
\n", "
64
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Use of Imaging Studies for Low Back Pain", "
CMS166v4
\n", "
4
\n", "", "
National Committee for Quality Assurance
\n", "
National Committee for Quality Assurance
\n", "
\nPhysician Performance Measure (Measures) and related data specifications \nwere developed by the National Committee for Quality Assurance (NCQA).\n
\n
\n", "
\n
\n\n
\n", "
b6016b47-b65d-4be0-866f-1d397886ca89
\n", "
0052
\n", "
\nPercentage of patients 18-50 years of age with a diagnosis of low back \npain who did not have an imaging study (plain X-ray, MRI, CT scan) within \n28 days of the diagnosis.\n
\n
\n", "
Individual Characteristic
\n", "
166
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Preventive Care and Screening: Cholesterol - Fasting Low Density Lipoprotein (LDL-C) Test Performed", "
CMS61v1
\n", "
1
\n", "
Cholesterol Screening A
\n", "
Quality Insights of Pennsylvania
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the measure specifications for \nconvenience. Users of the proprietary code sets should obtain all necessary \nlicenses from the owners of these code sets. Quality Insights of Pennsylvania \ndisclaims all liability for use or accuracy of any Current Procedural Terminology \n(CPT [R\n
\n
\n", "
\n
\n\n
\n", "
0a7f0278-a05c-40aa-94a4-70ec44f5c568
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 20 through 79 years whose risk factors have \nbeen assessed and a fasting LDL-C test has been performed.\n
\n
\n", "
Individual Characteristic
\n", "
61
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Bipolar Disorder and Major Depression: Appraisal for alcohol or chemical substance use", "
CMS169v3
\n", "
3
\n", "", "
Center for Quality Assessment & Improvement in Mental Health (CQAIMH)
\n", "
Center for Quality Assessment & Improvement in Mental Health (CQAIMH)
\n", "
\nThis measure is copyrighted by CQAIMH.  It may be used for research, teaching, \nand quality measurement / improvement activities  provided the following:\n
\n
\n", "
\n
\n\n
\n", "
b99aaef6-7889-4aba-85fc-5a2b739dd098
\n", "
0110
\n", "
\nPercentage of patients with depression or bipolar disorder with evidence \nof an initial assessment that includes an appraisal for alcohol or chemical \nsubstance use.\n
\n
\n", "
Individual Characteristic
\n", "
169
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Functional Status Assessment for Complex Chronic Conditions", "
CMS90v4
\n", "
4
\n", "", "
National Committee for Quality Assurance
\n", "
Centers for Medicare & Medicaid Services
\n", "
\nLimited proprietary coding is contained in the Measure specifications for \nuser convenience. Users of proprietary code sets should obtain all necessary \nlicenses from the owners of the code sets.  NCQA disclaims all liability \nfor use or accuracy of any CPT or other codes contained in the specifications.\n
\n
\n", "
\n
\n\n
\n", "
bb9b8ef7-0354-40e0-bec7-d6891b7df519
\n", "
Not Applicable
\n", "
\nPercentage of patients aged 65 years and older with heart failure who completed \ninitial and follow-up patient-reported functional status assessments\n
\n
\n", "
Individual Characteristic
\n", "
90
\n", "
InProgress
\n", "
PROCESS
\n", "
CY 2014 EP
\n"], ["Falls: Screening for Future Fall Risk", "
CMS139v3
\n", "
3
\n", "", "
National Committee for Quality Assurance/American Medical Association-convened Physician Consortium for Performance Improvement(R) (AMA-PCPI)
\n", "
National Committee for Quality Assurance
\n", "
\nCopyright 2013 National Committee for Quality Assurance (NCQA) and American \nMedical Association. All Rights Reserved.\n
\n
\n", "
\n
\n\n
\n", "
bc5b4a57-b964-4399-9d40-667c896f31ea
\n", "
0101
\n", "
\nPercentage of patients 65 years of age and older who were screened for \nfuture fall risk during the measurement period.\n
\n
\n", "
Individual Characteristic
\n", "
139
\n", "
Complete
\n", "
PROCESS
\n", "
CY 2014 EP
\n"]]}